var title_f16_46_17120="CNS histoplasmosis MRI";
var content_f16_46_17120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated histoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse enhancing brain lesions in disseminated histoplasmosis. Head and spinal cord MRI showed gadolinium-enhancing lesions in the cerebrum, cerebellum, brainstem, and spinal cord in a patient with mental status changes, cerebellar abnormalities, and loss of sensation in the left leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Wheat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17120=[""].join("\n");
var outline_f16_46_17120=null;
var title_f16_46_17121="Bipolar radiofrequency ablation 2";
var content_f16_46_17121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Bipolar radiofrequency endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Purdon, TF. NovaSure System Bipolar Radio Frequency Technology: Very short procedure time. OBG Management 2005. Copyright &copy; 2005 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17121=[""].join("\n");
var outline_f16_46_17121=null;
var title_f16_46_17122="Patient information: Alcohol and illegal drug use in pregnancy (The Basics)";
var content_f16_46_17122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/39/31346\">",
"         Patient information: Cocaine use disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/40/38529\">",
"         Patient information: Fetal alcohol syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/54/18274\">",
"         Patient information: Marijuana use and addiction (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/21/7506\">",
"         Patient information: Prescription drug abuse (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/23/4468\">",
"         Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Alcohol and illegal drug use in pregnancy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H86894695\">",
"      <span class=\"h1\">",
"       What can happen if I drink alcohol or use illegal drugs during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Drinking alcohol or taking illegal drugs during pregnancy can cause serious problems in your baby. Women should stop drinking alcohol and taking any illegal drugs",
"      <strong>",
"       before",
"      </strong>",
"      they try to get pregnant. This is important because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Even small amounts of alcohol or illegal drugs can be harmful to a pregnancy.",
"       </li>",
"       <li>",
"        Women do not always know they are pregnant for the first few weeks of their pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86894710\">",
"      <span class=\"h1\">",
"       What problems can happen if I drink alcohol during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Babies of mothers who drink alcohol during pregnancy can have fetal alcohol syndrome (also called &ldquo;FAS&rdquo;). This condition causes brain damage and growth problems. Compared with normal babies, babies with FAS tend to weigh less, have smaller heads, and be very fussy. When they grow up, they have life-long problems in how they think and act.",
"     </p>",
"     <p>",
"      Drinking alcohol during pregnancy can also make women more likely to have a &ldquo;stillbirth.&rdquo; A stillbirth is when a baby dies before it is born, in the second half of pregnancy (after 20 weeks).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86894725\">",
"      <span class=\"h1\">",
"       What problems can happen if I take illegal drugs during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on which illegal drug you take, when you take it, how much of it you take, and for how long. Not every woman who uses an illegal drug during pregnancy has extra problems. But many women&mdash;and their babies&mdash;do.",
"     </p>",
"     <p>",
"      The problems can also depend on other things, such as whether the mother smokes or drinks alcohol while taking illegal drugs.",
"     </p>",
"     <p>",
"      Doctors do not know for sure exactly what each illegal drug does to a pregnancy or a growing baby. That&rsquo;s because it is a very hard thing to study. Women who use illegal drugs during pregnancy often use more than 1 drug. They also tend to have other problems in addition to drug use. If a mother who uses more than 1 drug has problems with her pregnancy, it is tough to know for sure which drug caused which problem. And the problems might be caused by something other than her drug use.",
"     </p>",
"     <p>",
"      Despite these issues, there is enough good evidence to convince doctors that women should avoid all illegal drugs and alcohol during pregnancy. There is also good proof that the following illegal drugs can cause certain problems:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Heroin &ndash; Women who use heroin during pregnancy are at risk for many problems that can be dangerous for them and their babies. For example, these women can get infections that also infect the baby. The babies of mothers who use heroin can weigh less than normal or have a serious problem called &ldquo;opioid withdrawal syndrome&rdquo; when they are born.",
"       </li>",
"       <li>",
"        Cocaine &ndash; Pregnant women who take cocaine are more likely to have problem with the placenta. The placenta is the organ that forms between the mother and her baby during pregnancy. It brings the baby nutrients and oxygen and carries away waste. Using cocaine can cause the placenta to separate from the mother&rsquo;s uterus before delivery. This can be harmful for the mother and baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies born to mothers who use cocaine during pregnancy have a higher chance of being born too early (called &ldquo;premature&rdquo;) or being too small. These problems can affect the baby&rsquo;s feeding, sleeping, breathing, vision, and hearing.",
"     </p>",
"     <p>",
"      Using other illegal drugs, such as marijuana or methamphetamine, during pregnancy might also cause problems for the baby either at birth or later in life. More research is needed to understand how these drugs affect pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86894742\">",
"      <span class=\"h1\">",
"       What should I do if I am pregnant and already use alcohol or illegal drugs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant and drink alcohol or use illegal drugs, speak to your doctor or nurse. He or she can give you advice on the best and safest way to quit. If you use alcohol or heroin a lot, stopping suddenly can be dangerous for you or your baby. Your doctor or nurse can help you get off alcohol or heroin safely, so that your baby can be as healthy as possible. As part of this process, you might need to take certain medicines. Your doctor or nurse can also put you in touch with counselors or other people you can call for support.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H86894759\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/40/38529?source=see_link\">",
"       Patient information: Fetal alcohol syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=see_link\">",
"       Patient information: Marijuana use and addiction (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/39/31346?source=see_link\">",
"       Patient information: Cocaine use disorder (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=see_link\">",
"       Patient information: Prescription drug abuse (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"       Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/46/17122?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85731 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17122=[""].join("\n");
var outline_f16_46_17122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86894695\">",
"      What can happen if I drink alcohol or use illegal drugs during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86894710\">",
"      What problems can happen if I drink alcohol during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86894725\">",
"      What problems can happen if I take illegal drugs during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86894742\">",
"      What should I do if I am pregnant and already use alcohol or illegal drugs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86894759\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/39/31346?source=related_link\">",
"      Patient information: Cocaine use disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/40/38529?source=related_link\">",
"      Patient information: Fetal alcohol syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/54/18274?source=related_link\">",
"      Patient information: Marijuana use and addiction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=related_link\">",
"      Patient information: Prescription drug abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=related_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17123="Gentamicin (topical): Drug information";
var content_f16_46_17123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gentamicin (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38835?source=see_link\">",
"    see \"Gentamicin (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/20/31042?source=see_link\">",
"    see \"Gentamicin (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8107115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Gentamicin;",
"     </li>",
"     <li>",
"      ratio-Gentamicin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8107348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Aminoglycoside;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8107262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dermatologic infections:",
"     </b>",
"     Topical: Apply 3-4 times/day to affected area",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8107261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/20/31042?source=see_link\">",
"      see \"Gentamicin (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Dermatologic infections:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8107263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.1% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.1% (15 g, 30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8107129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8107130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically to treat superficial infections of the skin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8107104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gentamicin may be confused with gentian violet, kanamycin, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8107190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8107186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gentamicin or other aminoglycosides",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8107187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection; discontinue if superinfection is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Not intended for long-term therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8107210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9749648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered I.M. or I.V., gentamicin crosses the placenta and produces detectable serum levels in the fetus. Refer to the Gentamicin (Systemic) monograph for details. Systemic absorption following topical application would be required in order for gentamicin to cross the placenta and reach the fetus. Gentamicin is measurable in the serum following topical application to burn patients.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9749651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered I.M., gentamicin enters breast milk; however, it is not well absorbed when taken orally.  Refer to the Gentamicin (Systemic) monograph for details.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8107338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Gentamicin Sulfate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $15.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Gentamicin Sulfate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $15.59",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gamicin (TW);",
"     </li>",
"     <li>",
"      Garalone (PT);",
"     </li>",
"     <li>",
"      Garamicina (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Garamycin (CH, CZ, FI, HK, ID, MY, NL, NO, PH, RU, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Gentaderm (AR);",
"     </li>",
"     <li>",
"      Gental (TH);",
"     </li>",
"     <li>",
"      Gentalyn (IT, VE);",
"     </li>",
"     <li>",
"      Gentalyn Crema (CN);",
"     </li>",
"     <li>",
"      Gentamerck (ID);",
"     </li>",
"     <li>",
"      Gentamina (PY);",
"     </li>",
"     <li>",
"      Gentatrim (IL);",
"     </li>",
"     <li>",
"      Geomycine (BE);",
"     </li>",
"     <li>",
"      Ikagen (ID);",
"     </li>",
"     <li>",
"      Lyramycin (IN);",
"     </li>",
"     <li>",
"      Miragenta (CO);",
"     </li>",
"     <li>",
"      Miramycin (SG, TH);",
"     </li>",
"     <li>",
"      Qutacin (TW);",
"     </li>",
"     <li>",
"      Refobacin (DE);",
"     </li>",
"     <li>",
"      Skinfect (TH);",
"     </li>",
"     <li>",
"      Sulmycin (DE);",
"     </li>",
"     <li>",
"      Versigen (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8107232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9749646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Systemic absorption is reported following topical application to burn patients.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17123/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9143 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17123=[""].join("\n");
var outline_f16_46_17123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107115\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107348\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107262\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107261\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107263\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107336\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107130\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107104\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107190\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107187\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299398\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107210\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749648\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749651\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107338\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961977\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107232\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749646\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/21/3412?source=related_link\">",
"      Gentamicin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/23/28020?source=related_link\">",
"      Gentamicin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/36/37443?source=related_link\">",
"      Gentamicin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/47/761?source=related_link\">",
"      Gentamicin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/8/18564?source=related_link\">",
"      Gentamicin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/63/8185?source=related_link\">",
"      Gentamicin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38835?source=related_link\">",
"      Gentamicin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/20/31042?source=related_link\">",
"      Gentamicin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17124="Cromolyn sodium (ophthalmic): Patient drug information";
var content_f16_46_17124=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=see_link\">",
"     see \"Cromolyn sodium (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=see_link\">",
"     see \"Cromolyn sodium (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Opticrom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cromolyn sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep taking this drug to stop the allergy. Once signs start, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11623 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17124=[""].join("\n");
var outline_f16_46_17124=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030380\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030379\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030384\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030385\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030387\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030382\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030383\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030388\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030389\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/24/35202?source=related_link\">",
"      Cromolyn sodium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17125="Guaifenesin and dextromethorphan: Pediatric drug information";
var content_f16_46_17125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin and dextromethorphan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?30/0/30726?source=see_link\">",
"    see \"Guaifenesin and dextromethorphan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/7/40052?source=see_link\">",
"    see \"Guaifenesin and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cheracol&reg; D [OTC];",
"     </li>",
"     <li>",
"      Cheracol&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Coricidin HBP&reg; Chest Congestion and Cough [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Double Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Fenesin DM IR [OTC];",
"     </li>",
"     <li>",
"      Guaicon DMS [OTC];",
"     </li>",
"     <li>",
"      Iophen DM-NR [OTC];",
"     </li>",
"     <li>",
"      Kolephrin&reg; GG/DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Robafen DM Clear [OTC];",
"     </li>",
"     <li>",
"      Robafen DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Maximum Strength Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Sugar-Free Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Safe Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Senior [OTC];",
"     </li>",
"     <li>",
"      Silexin [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM DAS [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44E [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough &amp; Chest Congestion [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Pediatric Formula 44E [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM E;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Expectorant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/0/30726?source=see_link\">",
"      see \"Guaifenesin and dextromethorphan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (dose expressed in mg of",
"     <b>",
"      dextromethorphan",
"     </b>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1-2 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 60-120 mg/day divided every 6-8 hours or as extended release product 30-60 mg every 12 hours; not to exceed 120 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenesin DM IR: Guaifenesin 400 mg and dextromethorphan hydrobromide 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade; DM: Guaifenesin 400 mg and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coricidin HBP&reg; Chest Congestion and Cough: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid&rsquo;s Cough Mini-Melts&trade;: Guaifenesin 100 mg and dextromethorphan hydrobromide 5 mg per packet (12s) [contains magnesium 6 mg/pack, phenylalanine 2 mg/packet, sodium 3 mg/packet; orange cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; DM Maximum Strength: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Double Tussin DM: Guaifenesin 300 mg and dextromethorphan hydrobromide 20  mg per 5 mL (120 mL, 480 mL) [dye free, ethanol free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iophen DM-NR: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (480 mL) [contains propylene glycol, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kolephrin&reg; GG/DM: Guaifenesin 150 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [ethanol free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid&rsquo;s Cough: Guaifenesin 100 mg and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL) [contains propylene glycol, sodium 3 mg/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Safe Tussin&reg; DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 15 mg per 5 mL (120 mL) [contains benzoic acid, phenylalanine 4.2 mg/5 mL, and propylene glycol; orange and mint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Senior: Guaifenesin 200 mg and dextromethorphan hydrobromide 15 mg per 5 mL (120 mL) [ethanol free, sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; 44E: Guaifenesin 200 mg and dextromethorphan hydrobromide 20 mg per 15 mL (120 mL, 235 mL) [contains ethanol, sodium 31 mg/15 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Mucus Control DM: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 15 mL (295 mL) [contains propylene glycol, sodium 25 mg/15 mL, sodium benzoate; citrus blend flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Nature Fusion&trade; Cough &amp; Chest Congestion: Guaifenesin 200 mg and dextromethorphan hydrobromide 20 mg per 30 mL (236 mL) [dye free, ethanol free, gluten free; contains propylene glycol, sodium 36 mg/30 mL; honey flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Pediatric Formula 44E: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 15 mL (120 mL) [ethanol free; contains sodium 30 mg/15 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (5 mL, 10 mL, 120 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cheracol&reg; D: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 180 mL) [contains benzoic acid, ethanol 4.75%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cheracol&reg; Plus: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [contains benzoic acid, ethanol 4.75%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin-DM DAS-Na: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin-DM DAS-Na Maximum Strength: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Guaicon DMS: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (10 mL) [ethanol free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Tussin DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL, 237 mL, 473 mL) [ethanol free, contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL, 480 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen DM Clear: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Cough + Chest Congestion DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL ( 120 mL, 240 mL) [contains menthol, propylene glycol, sodium 7 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Sugar-Free Cough + Chest Congestion DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [sugar free; contains  propylene glycol, sodium 3 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Maximum Strength Cough + Chest Congestion DM: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL) [contains menthol, propylene glycol, sodium 5 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silexin: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (45 mL) [ethanol free, sugar free)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL, 480 mL) [strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin DM DAS: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Guaifenesin 1000 mg and dextromethorphan hydrobromide 60 mg; guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silexin: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; DM: Guaifenesin 600 mg and dextromethorphan hydrobromide 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; DM Maximum Strength: Guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral [scored]: Guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to meals, with a large quantity of fluid to ensure proper effect; do not crush, chew, or break extended release tablets",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary control of cough due to minor throat and bronchial irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benylin&reg; may be confused with Benadryl&reg;, Ventolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, dextromethorphan, or any component; use within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain phenylalanine which must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of sodium benzoate products in neonates",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Antitussive effect: Oral (rapid release formulation): 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Dextromethorphan is rapidly absorbed from the GI tract",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/7/40052?source=see_link\">",
"      see \"Guaifenesin and dextromethorphan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify healthcare provider if cough persists for greater than 7 days or if cough is associated with a fever, rash, or persistent headache",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17125/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13345 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17125=[""].join("\n");
var outline_f16_46_17125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177720\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059117\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059112\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177707\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177694\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059121\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059120\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177743\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177741\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059125\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059111\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059110\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177702\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177714\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059109\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059123\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059124\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059116\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/0/30726?source=related_link\">",
"      Guaifenesin and dextromethorphan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/7/40052?source=related_link\">",
"      Guaifenesin and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17126="Iopromide: Drug information";
var content_f16_46_17126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iopromide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/24/3460?source=see_link\">",
"    see \"Iopromide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ultravist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14457201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ultravist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum recommended total dose of iodine is 86 g. Individualize dose based upon patient's age, body weight, size of the vessel, and the rate of blood flow within the vessel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aortography and visceral angiography:",
"     </b>",
"     Intravascular (370 mg iodine/mL): Volume and rate of administration based on blood flow and specific characteristics of vessels being studied; maximum dose for procedure: 225 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cerebral arteriography:",
"     </b>",
"     Intravascular (300 mg iodine/mL): Maximum dose for procedure: 150 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carotid artery visualization: 3-12 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vertebral artery visualization: 4-12 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aortic arch injection: 20-50 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coronary arteriography and left ventriculography:",
"     </b>",
"     Intravascular (370 mg iodine/mL): Maximum dose for procedure: 225 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Left coronary: 3-14 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Right coronary: 3-14 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Left ventricle: 30-60 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-arterial digital subtraction angiography:",
"     </b>",
"     Intravascular (150 mg iodine/mL): Maximum dose for procedure: 250 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carotid arteries: 6-10 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vertebral: 4-8 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aorta: 20-50 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major branches of the abdominal aorta: 2-20 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral arteriography:",
"     </b>",
"     Intravascular (300 mg iodine/mL): Maximum dose for procedure: 250 mL.",
"     <b>",
"      Note:",
"     </b>",
"     The artery needs a pulse to be injected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Subclavian or femoral artery: 5-40 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aortic bifurcation for distal runoff 25-50 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contrast-enhanced CT:",
"     </b>",
"     I.V. (300 mg iodine/mL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head: 50-200 mL; maximum dose for procedure: 200 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body: 50-200 mL (usual dose for infusion is 100-200 mL);",
"     <b>",
"      Note:",
"     </b>",
"     Can be given by bolus injection, by rapid infusion, or both; maximum dose for procedure: 200 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Excretory urography (normal renal function):",
"     </b>",
"     I.V. (300 mg iodine/mL): 1 mL/kg; maximum dose for procedure: 100 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral venography:",
"     </b>",
"     I.V. (240 mg iodine/mL): Minimum amount to clearly visualize the structure under examination; maximum dose for procedure: 250 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cardiac chambers and related arteries:",
"     </b>",
"     Children &gt;2 years: I.V. (370 mg iodine/mL): 1-2 mL/kg; maximum dose for procedure: 4 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contrast-enhanced CT:",
"     </b>",
"     Children &gt;2 years: I.V. (300 mg iodine/mL): 1-2 mL/kg; maximum dose for procedure: 3 mL/kg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use caution in renal impairment and in setting of combined renal and hepatic disease. Manufacturer recommends using lowest necessary dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravist&reg;: Iodine 150 mg/mL (50 mL [DSC]) [contains edetate calcium disodium; provides iopromide 311.7 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravist&reg;: Iodine 240 mg/mL (50 mL [DSC], 100 mL, 150 mL [DSC], 200 mL) [contains edetate calcium disodium; provides iopromide 498.72 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravist&reg;: Iodine 300 mg/mL (50 mL, 75 mL [DSC], 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium; provides iopromide 623.4 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultravist&reg;: Iodine 370 mg/mL (50 mL, 75 mL [DSC], 100 mL, 125 mL [DSC], 150 mL, 200 mL, 250 mL, 500 mL) [contains edetate calcium disodium; provides iopromide 768.86 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions for intra-arterial injections should be as close to body temperature as possible. Injection rates should be about equal to the flow rate in the vessel being injected. Allow sufficient time between each large injection. Visually inspect prior to use; do not use if discolored, if particulate matter is present, or if containers are defective.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F183965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be mixed with or injected into any lines containing other drugs or solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enhance imaging in cerebral arteriography and peripheral arteriography; coronary arteriography and left ventriculography, visceral angiography and aortography; contrast-enhanced computed tomographic imaging of the head and body, excretory urography, intra-arterial digital subtraction angiography, peripheral venography",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilatation (4%), chest pain (3%), hypertension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), pain (2%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4%), vomiting (2%), abnormal taste (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary urgency (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site hematoma (3%), injection site pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Abdominal pain, agitation, amnesia, anaphylaxis, angioedema (pediatric), anxiety, aphasia, apnea, arthralgia, asthenia, asthma, AV block (complete), bradycardia, brain edema (pediatric), bullous eruption (delayed), erythema (delayed), chills, confusion, CHF, conjunctivitis (pediatric), constipation, cough increased, coronary thrombosis, depression, diabetes insipidus (pediatric), diaphoresis increased, diarrhea, dry mouth, dysmenorrhea, dyspepsia, dyspnea, dysuria, emotional lability, epistaxis (pediatric), facial edema, fever, fixed eruptions (pediatric), hematuria, hemopericardium, hypersensitivity, hypertonia, hypoesthesia, hypotension, hypotonia, hypovolemic shock, hypoxemia, hypoxia (pediatric), incoordination, injection site reactions (edema, erythema, rash, warm feeling), insomnia, joint effusion (pediatric), kidney pain, lacrimation disorder, laryngeal edema, malaise, migraine (pediatric), mucosal swelling (pediatric), muscle cramping (pediatric), myasthenia, mydriasis, neck pain, nephropathy, neuropathy, papular rash (delayed), paresthesia, pharyngitis, polydypsia, premature ventricular contractions, pruritus, pulmonary hypertension, rash, renal failure, salivation, seizure, skin discoloration, skin eruption (delayed), sneezing (delayed), somnolence, sore throat, speech disorder, syncope, tachycardia, tenesmus, thrombosis, tongue paralysis, tremor, urticaria, urinary retention, vascular anomaly, ventricular fibrillation, vertigo (pediatric), visual field defect, wheals (delayed)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not indicated for intrathecal use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pediatrics: Prolonged fasting and laxative use prior to administration of iopromide",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: May cause serious and potentially fatal anaphylactoid reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood-brain barrier disruption: In patients with known or suspected blood-brain barrier disruption or with normal blood-brain barriers and renal failure, iodinated contrast agents have been associated with blood-brain barrier disruption and accumulation of contrast in the brain; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contrast media nephropathy: Contrast agents may cause acute renal impairment defined as a serum creatinine rise of 0.5 mg/dL or increase of 50% over baseline. Risk factors include concurrent use of nephrotoxic agents, dehydration, diabetes, heart failure, high-dose contrast, and pre-existing renal impairment. In patients at risk, minimize dose and monitor renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed reactions: May cause delayed adverse reactions; monitor patients for 30-60 minutes after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reaction: Risks for an immune reaction include previous reaction to contrast, known sensitivity to iodine and known allergies (asthma, hay fever and food allergies), other hypersensitivities, and underlying immune disorder. Skin testing cannot be relied upon and may be dangerous. Treatment for severe reactions should be immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Serious thromboembolic events have been reported during angiographic procedures with both ionic and nonionic contrast agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; these patients may have altered renal blood flow, increasing risk of nephrotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, especially those with concomitant renal dysfunction or when using both oral and I.V. contrast agents in close proximity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple myeloma: Use with caution in patients with multiple myeloma; may worsen renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma: Use with extreme caution in patients with known or suspected pheochromocytoma. Dose injected should be kept to a minimum to minimize exposure; monitor blood pressure closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; clearance is reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disease: Use with caution in patients with sickle cell disease; may promote sickling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid disease; thyroid storm has been reported in patients with history of hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; General anesthesia: Use with caution in patients undergoing general anesthesia while receiving contrast agents; may be an increased risk of adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients with age-related renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &le;2 years of age. Pediatric patients may have an increased risk of adverse effects, especially patients with asthma, sensitivity to allergens or medications, heart disease, or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: For I.V. or intra-arterial use only.",
"     <b>",
"      [U.S. Boxed Warning]: May be fatal if given intrathecally.",
"     </b>",
"     Avoid extravasation, especially in patients with severe arterial or venous disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Adequately hydrate patient prior to and following administration. Delay intravenous contrast agent administration in patients who have recently received a cholecystographic contrast agent. In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies do not show evidence of direct fetal harm. Embryolethality was observed, but may be related to maternal toxicity. Safety has not been established in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ultravist Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31% (50 mL): $19.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (200 mL): $91.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     62% (500 mL): $474.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     77% (500 mL): $474.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coronary arteriography: ECG (coronary arteriography); vital signs; signs and symptoms of hypersensitivity; renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Clarograf (AR);",
"     </li>",
"     <li>",
"      Prosure (KP);",
"     </li>",
"     <li>",
"      Ultravist (AT, AU, BE, BG, CH, CL, CR, CZ, DE, DK, DO, EC, FI, FR, GR, GT, HN, IE, IL, IN, IT, KP, NI, NL, NO, NZ, PA, PE, PL, PT, RU, SE, SG, SV, TR, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iopromide opacifies vessels in its path of flow, permitting radiographic visualization of internal structures.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 16 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Main phase: 2 hours, terminal phase: 6.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intravascular: Contrast enhancement: 15-120 seconds after bolus injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intravenous: Contrast enhancement: Kidneys: 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 97% (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Academy Position Statement: The Risk of Severe Allergic Reactions from the Use of Potassium Iodide for Radiation Emergencies,&rdquo; Adverse Reactions to Foods Committee and the Adverse Reactions to Drugs and Biologicals Committee. Available at file://www.aaaai.org/media/resources/academy_statements/position_statements/potassium_iodide.asp. Accessed October 24, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. Available at file://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cutronea P, Polimeni G, Curcuruto R, et al, &ldquo;Adverse Reactions to Contrast Media: An Analysis From Spontaneous Reporting Data,&rdquo;",
"      <i>",
"       Pharmacol Res",
"      </i>",
"      , 2007, 56(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/17482832/pubmed\" id=\"17482832\" target=\"_blank\">",
"        17482832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy SW, Barrett BJ, and Parfrey PS, &ldquo;Contrast Nephropathy,&rdquo;",
"      <i>",
"       J Am Soc Nephrol",
"      </i>",
"      , 2000, 11(1):177-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/46/17126/abstract-text/10616853/pubmed\" id=\"10616853\" target=\"_blank\">",
"        10616853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8880 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17126=[""].join("\n");
var outline_f16_46_17126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708950\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183947\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14457201\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183960\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183949\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183955\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062780\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962266\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962267\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183928\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183916\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183930\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183965\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183929\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174550\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183958\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183933\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183918\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299532\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183922\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183925\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183935\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183950\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323206\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183936\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183917\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183932\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/24/3460?source=related_link\">",
"      Iopromide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17127="The effects of medications on sleep quality and sleep architecture";
var content_f16_46_17127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The effects of medications on sleep quality and sleep architecture",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Timothy Roehrs, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Thomas Roth, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17127/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/46/17127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any medication that passes through the blood-brain barrier has the potential to alter the quality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    architecture of sleep:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality is the degree to which restful sleep is maintained during the night and the individual feels refreshed on waking and throughout the day. Traditional measures of sleep quality include latency until sleep onset, wakefulness after sleep onset,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the duration of sleep.",
"     </li>",
"     <li>",
"      Sleep architecture is the structure of sleep. It is cyclical, composed of rapid eye movement (REM) and several non-REM sleep stages, and assessed primarily by electroencephalography (EEG) during polysomnography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medication-induced changes in sleep quality",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    architecture are not synonymous with a sleep disturbance; in some cases the changes may be therapeutic, while in others they may be benign or not well understood. The effects of medications that target the central nervous system, cardiovascular system, or respiratory system on sleep quality and sleep architecture are reviewed here. The stages and architecture of normal sleep are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"     \"Stages and architecture of normal sleep\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CENTRAL NERVOUS SYSTEM MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly prescribed medications that act on the central nervous system (CNS) and can affect sleep include benzodiazepines, antiepileptics, antidepressants, analgesics, and CNS stimulants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Benzodiazepines and benzodiazepine receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ) and benzodiazepine receptor agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    ) are commonly prescribed sedative-hypnotic medications used to treat insomnia or anxiety. Both types of agents facilitate gamma-aminobutyric acid (GABA)-mediated inhibition of cell firing by binding to a subunit of the GABA receptor complex called the benzodiazepine receptor. The GABA receptor complex is present throughout the brain, including the ventral lateral preoptic area that controls sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; All benzodiazepines and benzodiazepine receptor agonists improve sleep quality by reducing the time to sleep onset. The longer-acting agents also improve sleep quality by reducing wakefulness after sleep onset and increasing the total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; Benzodiazepines and benzodiazepine receptor agonists reduce the amount of stage N1 sleep (ie, light sleep), which is considered a therapeutic effect. They may also increase spindle activity during stage N2 sleep (and increase N2 percent). Benzodiazepines are potent suppressors of stage N3 sleep (ie, deep sleep or slow wave sleep), but the benzodiazepine receptor agonists are not. Finally, benzodiazepines and benzodiazepine receptor agonists may modestly reduce REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Patients report that their ease of falling asleep is improved, awakenings are reduced, and sleep time is increased. During the day they experience less sleepiness, greater ability to concentrate, and better daytime performance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discontinuation may be associated with rebound insomnia (ie, difficulty initiating or maintaining sleep that is worse than that experienced prior to the use of the medication), particularly if high doses are used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Melatonin and melatonin receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     Ramelteon",
"    </a>",
"    is a melatonin receptor agonist that binds to the melatonin 1 and 2 receptors, inhibiting the wakefulness-promoting activity of the suprachiasmatic nucleus. It is generally prescribed for the treatment of sleep onset insomnia (ie, difficulty falling asleep). In contrast, melatonin binds to all three melatonin receptors and is less potent than ramelteon. It is considered a better chronobiotic agent than ramelteon, meaning that it is better at phase shifting circadian rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, melatonin may be useful in circadian rhythm disorders, such as jet lag due to eastward travel and delayed sleep phase syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of insomnia\", section on 'Melatonin agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link&amp;anchor=H6#H6\">",
"     \"Jet lag\", section on 'Exogenous melatonin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of insomnia\", section on 'Over-the-counter'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"       Ramelteon",
"      </a>",
"      reduces the latency to sleep onset and increases sleep duration, although its effects on sleep continuity are inconsistent. Melatonin also appears to reduce latency to sleep onset; however, its effects on sleep maintenance and duration are inconsistent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"       Ramelteon",
"      </a>",
"      reduces the amount of stage N1 sleep (ie, light sleep), which is considered a therapeutic effect, but it has no other effects on sleep architecture. In contrast, melatonin&rsquo;s effects on sleep architecture are inconsistent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Patients do not consistently experience increased sleep time or improved daytime function, but the ease of falling asleep improves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antiepileptic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic antiepileptic medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ) inhibit CNS activity, but the mechanisms of inhibition are poorly characterized. In contrast, the newer antiepileptic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) enhance GABA activity through various mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; The classic antiepileptic agents appear to decrease sleep latency and increase total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      may also decrease wakefulness after sleep onset. The effects of the newer agents on sleep quality are less certain due to a paucity of data. In separate studies,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      was associated with a trend toward fewer awakenings after sleep onset [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/6\">",
"       6",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      was shown to reduce sleep latency and increase total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/7\">",
"       7",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"       tiagabine",
"      </a>",
"      had inconsistent effects on wakefulness after sleep onset and total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; The classic antiepileptic drugs have variable effects on sleep architecture.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      appears to increase stage N3 sleep and reduce REM sleep.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       Phenobarbital",
"      </a>",
"      decreases REM sleep, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      increases stage N1 sleep and decreases stage N3 sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ]. The newer antiepileptic agents increase stage N3 sleep, while reducing REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; The clinical significance of enhancement of stage N3 sleep is controversial. Whether patients experience improved sleep restoration or daytime function is yet to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients develop rapid tolerance (ie, within a week) to the sleep-related effects of the classic antiepileptic agents, while tolerance to the newer agents is less evident [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressant medications include the tricyclic agents (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin antagonist reuptake inhibitors (SARIs), and selective serotonin reuptake inhibitors (SSRIs). Most antidepressants affect both sleep quality and sleep architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; Antidepressant agents have a variable effect on sleep quality, as some are sedating while others are stimulating. The tertiary TCAs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31271?source=see_link\">",
"       trimipramine",
"      </a>",
"      ) decrease the latency until sleep onset and wakefulness after sleep onset, whereas the secondary TCAs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      ) have little or no effect on either measure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ]. There is a paucity of data regarding the MAOIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8439?source=see_link\">",
"       isocarboxazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/42/20135?source=see_link\">",
"       phenelzine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/29/32215?source=see_link\">",
"       tranylcypromine",
"      </a>",
"      ) but, generally speaking, they appear to increase wakefulness after sleep onset and decrease total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ]. Studies of the effects of the SARIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      ) on sleep quality are notable for their inconsistency, with about half of studies showing improvements in measures of sleep quality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ]. Finally, the SSRIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ) appear to increase wakefulness after sleep onset and decrease the total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; All antidepressant agents suppress REM sleep, except the SARIs [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. This is characterized by an increased latency to the onset of REM sleep and a reduction in the percentage of REM sleep. This is particularly profound with the MAOIs [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ]. Understanding the effects of antidepressant agents on the other sleep stages is complicated by inconsistent data. Many studies suggest that the tertiary TCAs have no effect on stage N3 sleep, although at least one study showed increased stage N3 sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/4\">",
"       4",
"      </a>",
"      ]. Most studies have found that the SARI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , increased stage 3 sleep, while the other SARI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      , decreased stage 3 sleep. The SSRIs appear to increase stage 1 sleep.",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; It is hypothesized that REM suppression is the mechanism for the mood elevating effects of these drugs, since REM suppression occurs with most all antidepressants. However, this hypothesis is controversial. The clinical significance of stage N3 sleep enhancement is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tolerance to the",
"    <span class=\"nowrap\">",
"     anticholinergic/sedating",
"    </span>",
"    effects develops relatively rapidly (usually within a week or two), while the REM-suppressing effects persist. A REM sleep rebound and sleep disturbance can be experienced with the abrupt discontinuation of antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesic medications include opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ), nonsteroidal antiinflammatory drugs (NSAIDs), and antiinflammatory and antipyretic analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ). Some over-the-counter (OTC) sleeping aids and cold remedies include analgesics, usually acetaminophen combined with an antihistamine. The effects of analgesic medications on sleep quality and sleep architecture have been scarcely studied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; The effects of opioids on sleep quality differ among healthy individuals and those who are addicted to opioids. In healthy individuals, opioids have no effect on wakefulness after sleep onset or total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5,11\">",
"       5,11",
"      </a>",
"      ]. In contrast, among addicts, opioids increase wakefulness after sleep onset and decrease total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5,12\">",
"       5,12",
"      </a>",
"      ]. NSAIDs may impair sleep by inhibiting prostaglandin synthesis, which is believed to promote sleep. In one study of healthy individuals, NSAIDs were associated with increased wakefulness after sleep onset, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      was not associated with changes in any measure of sleep quality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; Opioids decrease stage N3 sleep and, at higher doses, also decrease REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ]. This was demonstrated by a double-blind cross-over trial of 42 healthy volunteers [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/11\">",
"       11",
"      </a>",
"      ]. Both sustained-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      decreased the percentage of total sleep time spent in stage N3 sleep, compared to placebo. Neither NSAIDs nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      have been shown to alter sleep architecture [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Patients who receive opioids for pain may not experience sleep disturbance, as seen in addicts and some healthy volunteer studies. Long-acting opiates increase daytime sleepiness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tolerance to these effects develops rapidly, usually within days. Despite the adverse effects that analgesics can have on sleep in healthy individuals, analgesics may improve sleep if pain is causing a sleep disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Central nervous system stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that stimulate the nervous system (eg, amphetamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    ) have profound effects on both the quality and architecture of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep quality &ndash; CNS stimulants increase the latency to sleep onset and increase wakefulness during the sleep period.",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; CNS stimulants increase stage N1 sleep and reduce both stage N3 and REM sleep.",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Patients develop daytime sleepiness due to reduced sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rapid tolerance develops to these effects on sleep quality and staging. Upon discontinuation of the drug, there may be increased sleepiness and a rebound in REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some over-the-counter medications contain ephedrine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    , which are similar in chemical structure to amphetamine. These agents have not been studied, but they probably also disrupt sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10244238\">",
"    <span class=\"h1\">",
"     ATYPICAL ANTIPSYCHOTIC MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotic medications are often used as hypnotics. Whereas the typical antipsychotic medications have only dopaminergic antagonism, the atypical antipsychotic medications have both serotonergic and dopaminergic antagonism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; Studies in healthy volunteers and patients with mood disorders or schizophrenia have found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      reduce both sleep latency and wake time after sleep onset. Thus, the atypical antipsychotic medications increase sleep time.",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; Atypical antipsychotic medications generally suppress REM sleep, while increasing amounts of stage N3.",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Owing to their long half-lives, daytime sedation occurs in 29 to 52 percent of patients receiving atypical antipsychotic medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARDIAC MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac medications with an effect on sleep include the beta adrenergic blockers and centrally acting alpha adrenergic agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers can be categorized as lipophilic or hydrophilic. The lipophilic agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    , while the hydrophilic agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    . Hydrophilic agents do not cross the blood brain barrier readily and, thus, have no sleep effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; Lipophilic beta blockers are associated with an increase in both the number of awakenings and the amount of awake time following sleep onset [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash; Lipophilic and hydrophilic beta blockers both suppress REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5,18\">",
"       5,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Lipophilic beta blockers are associated with daytime sleepiness, insomnia, hallucinations, and nightmares. This effect does not appear to be secondary to their effects on nighttime sleep alone, since daytime sleepiness is observed after daytime drug administration [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alpha adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the evidence regarding the impact of centrally acting alpha adrenergic receptor agonists on sleep comes from studies of one agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash; The effects of alpha adrenergic receptor agonists on sleep quality are uncertain due to inconsistent data. A study of hypertensive patients found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      decreased total sleep time, whereas a study in healthy individuals found that clonidine increased total sleep time [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       Clonidine",
"      </a>",
"      increases the number of shifts to stage N1 sleep or wakefulness, and also suppresses REM sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; The alpha adrenergic receptor agonists increase daytime sleepiness. This effect is observed after daytime drug administration and does not appear to be secondary to their effects on nighttime sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10620034\">",
"    <span class=\"h1\">",
"     PULMONARY MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary medications with an effect on sleep include the methylxanthines and corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is a methylxanthine that is used to treat stable obstructive airways disease and, less frequently, is used as a respiratory stimulant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=see_link\">",
"     \"Role of methylxanthines in the treatment of COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of apnea of prematurity\", section on 'Methylxanthine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep quality &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      delays sleep onset and increases wakefulness after sleep onset in healthy individuals. In patients with COPD and asthma, however, theophylline may have no deleterious effects on the quality of sleep. It is possible that the therapeutic effects of the drug on breathing improve sleep to such a degree that it offsets the deleterious effects of the medication on sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep architecture &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      increases stage N1 sleep, but no other effects on sleep architecture are observed.",
"     </li>",
"     <li>",
"      Patient-important effects &ndash; Patients who take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      experience improved sleep and improved daytime alertness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic corticosteroids are used to treat a variety of pulmonary diseases. They are widely believed to disrupt sleep, but this is based upon patient reports because their effects have not been well studied polysomnographically. The limited evidence that exists suggests that corticosteroids are associated with suppression of REM sleep and increased awakening after sleep onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17127/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. Inhaled corticosteroids do not appear to have the same adverse effects on sleep in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10619189\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any medication that passes through the blood-brain barrier has the potential to alter the quality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      architecture of sleep. Sleep quality is the degree to which restful sleep is maintained during the night and the individual feels refreshed on waking and throughout the day. Sleep architecture is the structure of sleep; it is cyclical and composed of both rapid eye movement (REM) and several non-REM sleep stages. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central nervous system medications that affect sleep quality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sleep architecture include benzodiazepines, benzodiazepine receptor agonists, antiepileptic agents, antidepressants, analgesics, and stimulants. The benzodiazepines and benzodiazepine receptor agonists are associated with improved ease of falling asleep, reduced awakenings, increased sleep time, less daytime sleepiness, better concentration, and better daytime performance. The other central nervous system medications have a variety of effects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Central nervous system medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac medications that affect sleep quality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sleep architecture include lipophilic beta adrenergic blockers and centrally acting alpha adrenergic agonists. Both are associated with daytime sleepiness, while the lipophilic beta adrenergic blockers are also associated with insomnia, hallucinations, and nightmares (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cardiac medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary medications known to affect sleep quality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sleep architecture include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and systemic corticosteroids. Theophylline is associated with improved sleep and improved daytime alertness, whereas corticosteroids are associated with increased awakening after sleep onset. (See",
"      <a class=\"local\" href=\"#H10620034\">",
"       'Pulmonary medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mendelson W. Hypnotic Medications: Mechanisms of Action and Pharmacologic Effects.. In: Principles and Practices of Sleep Medicine, Fifth, Kryger MH, Roth T, Dement WC.  (Eds), Elsevier Saunders, St. Louis, MO. 2011. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/2\">",
"      Roehrs TA, Randall S, Harris E, et al. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2012; 26:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/3\">",
"      Zee PC, Wang-Weigand S, Wright KP Jr, et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med 2010; 11:525.",
"     </a>",
"    </li>",
"    <li>",
"     Buysse DJ. Clinical Pharmacology of Other Drugs Used as Hypnotics.. In: Principles and Practices of Sleep Medicine., Fifth, Kryger MH, Roth T, Dement WC..  (Eds), Elsevier Saunders, St. Louis 2011. p.492.",
"    </li>",
"    <li>",
"     Schweitzer PK. Drugs that Disturb Sleep and Wakefulness.. In: Principles and Practices of Sleep Medicine., Fifth, Kryger MH, Roth T, Dement WC..  (Eds), Elsevier Saunders, St. Louis, MO. 2011. p.542.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/6\">",
"      Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia 2002; 43:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/7\">",
"      Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/8\">",
"      Walsh JK, Zammit G, Schweitzer PK, et al. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med 2006; 7:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/9\">",
"      Walsh JK, Perlis M, Rosenthal M, et al. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J Clin Sleep Med 2006; 2:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/10\">",
"      Young AH, Currie A. Physicians' knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiatry 1997; 58 Suppl 7:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/11\">",
"      Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/12\">",
"      Cronin AJ, Keifer JC, Davies MF, et al. Postoperative sleep disturbance: influences of opioids and pain in humans. Sleep 2001; 24:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/13\">",
"      Murphy PJ, Badia P, Myers BL, et al. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiol Behav 1994; 55:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/14\">",
"      Glidwell RN, Moorcroft WH, Lee-Chiong T. Comorbid insomnia: Reciprocal relationships and medication management. Sleep Med Clin 2010; 5:627.",
"     </a>",
"    </li>",
"    <li>",
"     Nihino S, Mignot E. Wake-promotig Medications: Basic Mechanisms and Pharmacology. In: Principles and Practices of Sleep Medicine, Fifth, Kryger MH, Roth T, Dement WC.  (Eds), Elsevier Saunders, St. Louis, MO 2011. p.510.",
"    </li>",
"    <li>",
"     O'Malley MB, Gleeson SK, Weir ID. Wake-promotig Medications: Efficacy and Adverse Effects. In: Principles and Practices of Sleep Medicine, Fifth, Kryger MH, Roth T, Dement WC.  (Eds), Elsevier Saunders, St. Louis, MO 2011. p.527.",
"    </li>",
"    <li>",
"     Roehrs T, Roth T. Medication and substance abuse. In: Principles and practice of sleep medicine, 5th ed, 2010. p.1512.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/18\">",
"      Rosen RC, Kostis JB. Biobehavioral sequellae associated with adrenergic-inhibiting antihypertensive agents: a critical review. Health Psychol 1985; 4:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/19\">",
"      Kostis JB, Rosen RC, Holzer BC, et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990; 102:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/20\">",
"      Kanno O, Clarenbach P. Effect of clonidine and yohimbine on sleep in man: polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalogr Clin Neurophysiol 1985; 60:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/21\">",
"      Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10 Suppl 1:165S.",
"     </a>",
"    </li>",
"    <li>",
"     Schweitzer PK. Drugs that disturb sleep and wakefulness. In: Principles and practice of sleep medicine, 4th ed, 2005. p.499.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17127/abstract/23\">",
"      Gillin JC, Jacobs LS, Fram DH, Snyder F. Acute effect of a glucocorticoid on normal human sleep. Nature 1972; 237:398.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7704 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17127=[""].join("\n");
var outline_f16_46_17127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10619189\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CENTRAL NERVOUS SYSTEM MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Benzodiazepines and benzodiazepine receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Melatonin and melatonin receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antiepileptic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Central nervous system stimulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10244238\">",
"      ATYPICAL ANTIPSYCHOTIC MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARDIAC MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alpha adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10620034\">",
"      PULMONARY MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10619189\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25031?source=related_link\">",
"      Role of methylxanthines in the treatment of COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17128="Mortality HTN under 65 years";
var content_f16_46_17128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Joint effect of systolic and diastolic blood pressure on mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among participants in the NHANES II who were &lt;65 years of age, the figure shows a three dimensional surface representing the relative risk for all-cause mortality (vertical axis) with different combinations of the diastolic blood pressure (right diagonal arrow axis) and the systolic blood pressure (left diagonal arrow axis). For a fixed diastolic blood pressure, for example, the effect of different systolic blood pressures can be evaluated by following the risk surface along lines parallel to the systolic blood pressure axis. This effect is known as the conditional effect of systolic blood pressure. Similarly, for a fixed systolic blood pressure, the conditional effect of diastolic blood pressure can be evaluated by following the risk surface along lines parallel to the diastolic blood pressure axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Pastor-Barriuso R, et al. Ann Intern Med 2003; 139:731.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17128=[""].join("\n");
var outline_f16_46_17128=null;
var title_f16_46_17129="Clinical manifestations and treatment of radiation-induced fibrosis";
var content_f16_46_17129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and treatment of radiation-induced fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Elisabeth Weiss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17129/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/46/17129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis can develop as a late effect of radiation therapy (RT) in skin and subcutaneous tissue, lungs, the gastrointestinal and genitourinary tracts, muscles, or other organs, depending upon the treatment site. Radiation-induced fibrosis may cause both cosmetic and functional impairment, which can lead to death or a significant deterioration in the quality of life.",
"   </p>",
"   <p>",
"    The development of radiation-induced fibrosis is influenced by multiple factors, including the radiation dose and volume, fractionation schedule, previous or concurrent treatments, genetic susceptibility, and comorbidities such as diabetes mellitus. Although radiation-induced fibrosis originally was assumed to be a slow, irreversible process, contemporary studies suggest that it is not necessarily a fixed process.",
"   </p>",
"   <p>",
"    The prevention of radiation-induced fibrosis has focused on improvements in RT technique, which have resulted in higher doses to the tumor target and decreased doses to normal tissue, thus potentially preventing the development of radiation-induced fibrosis. Furthermore, established radiation-induced fibrosis may be treatable with novel therapeutic approaches, particularly the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    and vitamin E.",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, clinical manifestations, prevention, and treatment of radiation-induced fibrosis will be discussed here. Radiation-induced changes in the lungs and gastrointestinal tract are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"     \"Diagnosis and management of chronic radiation enteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis is similar to inflammation, wound healing, and fibrosis of any origin. Typical histologic features include the presence of inflammatory infiltrates, particularly macrophages in the earlier stages of fibrosis, differentiation of fibroblasts into postmitotic fibrocytes, and changes in the vascular connective tissue with excessive production and deposition of extracellular matrix proteins and collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of fibrosis is mediated by cytokine expression that probably begins immediately after RT and continues for months or years. Inflammatory mediators that have been implicated include tumor necrosis factor-alpha (TNF-alpha) and interleukins 6 and 1 (IL-6 and IL-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Fibrogenic cytokines that modulate the proliferation and differentiation of fibroblasts and the synthesis of extracellular matrix proteins and matrix metalloproteinases (MMPs) include transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF). Other growth factors, such as the connective tissue growth factor (CTGF), which is secreted by fibroblasts and endothelial cells, also promote fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation-induced alterations of the vascular system, particularly damage to endothelial cells, appear to contribute significantly to late toxicity. Damage to the myocardium after radiotherapy for left-sided breast cancer has been associated with changes of the microvasculature resulting in reduced perfusion and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/8\">",
"     8",
"    </a>",
"    ]. Hyalinoid changes of the capillary wall and a rarefication of the capillary net are typically seen in fibrotic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIC FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RT parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of radiation-induced fibrosis is increased with higher radiation doses and larger treated volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The radiation dose that causes fibrosis can vary substantially in different tissues, as is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrosis in both connective and vascular tissues is generally associated with total radiation doses of 60 Gy or higher.",
"     </li>",
"     <li>",
"      In contrast, the heart is relatively sensitive to radiation, and relatively low doses of RT can cause peri-, myo- or endocardial fibrosis. Thus radiation doses to the whole heart should not exceed 40 Gy. Similarly, the lungs are relatively sensitive to radiation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"       \"Radiation-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The technique of RT administration can have a major effect on the dose of radiation received by normal tissues. Examples of situations where the risk of radiation-induced fibrosis is influenced by the RT technique include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin induration is more frequent in women treated with overlapping tangential breast fields and internal mammary lymph node fields [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of radiation-induced fibrosis is increased with high single doses of RT (eg, intraoperative radiation treatment, single fraction external beam RT, brachytherapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrosis may be more common when different RT techniques are combined. As an example, the combination of external beam RT with interstitial and intracavitary brachytherapy for gynecological tumors can cause radiation-induced fibrosis of the ureter and vagina, as well as late toxicity to the large and small bowel [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of multiple fractions per day increases the risk of radiation-induced fibrosis. In a randomized trial in patients with lung cancer, the risk of dysphagia was higher two years after treatment with hyperfractionated RT compared to conventional fractionation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postoperative as opposed to preoperative administration of RT is associated with an increased risk of late radiation complications in sarcoma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/10\">",
"       10",
"      </a>",
"      ]. In men with prostate cancer, patients with a history of abdominal surgery or a transurethral resection of the prostate (TURP) had an increased risk for late RT complications [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher doses of RT not only increase the incidence of fibrosis but also shorten the latent period until late sequelae are apparent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During RT planning, organ-specific guidelines are used to limit the dose to normal tissue. With this information, the risk for radiation-related sequelae can be estimated and volume-dependent dose limits generated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other factors influence the response to radiation, thus increasing the incidence of complications.",
"   </p>",
"   <p>",
"    Genetic variation in the response to radiation may be associated with an increased incidence of radiation-induced fibrosis. As an example, there is a higher risk of subcutaneous fibrosis in patients with breast cancer who have specific modifications of the ATM gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with other diseases associated with deficient DNA repair may also be more likely to develop symptoms of radiation-induced fibrosis.",
"   </p>",
"   <p>",
"    Patients with connective tissue diseases, such as scleroderma, rheumatoid arthritis, or systemic lupus erythematosus, may have an increased incidence of toxicity from RT, but the magnitude of this risk is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In a review of eight observational studies that included 404 patients with connective tissue diseases who were treated with RT, there was a statistically significant association with late RT-induced complications in normal tissues (fibrosis, osteonecrosis, bone fractures) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors may contribute to the association of RT complications with connective tissue diseases. The development of radiation-induced fibrosis may be affected by the concurrent use of medications such as corticosteroids and cytotoxic drugs. In addition to increasing RT toxicity, these drugs can cause osteopenia and bone fractures, which may be attributed to RT. Sequelae of connective tissue disorders, such as dry eye and dry mouth symptoms in Sj&ouml;grens syndrome, may mimic radiation-induced fibrosis.",
"   </p>",
"   <p>",
"    Diabetes mellitus increases the risk of late RT complications in normal tissue. Several reports have described a higher risk for gastrointestinal and particularly genitourinary toxicity in diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These observations have been attributed to changes in the microvasculature and alterations in blood viscosity, which result in decreased tissue perfusion and impaired normal tissue repair.",
"   </p>",
"   <p>",
"    Combining RT with systemic cancer treatment has been assumed to cause a higher risk of radiation-induced toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/26\">",
"     26",
"    </a>",
"    ], but clinical studies have given conflicting results. The following illustrate the range of results that have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial comparing sequential versus concurrent chemotherapy in breast cancer patients receiving RT, the risk for late effects including subcutaneous fibrosis was significantly increased in those receiving concurrent chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of eight studies of women with cervical cancer who were treated either with RT plus chemotherapy or with RT alone found that there were no significant differences in the rates of late complications in seven of eight trials [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In women with breast cancer, the incidence of lung fibrosis was increased after combined RT and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . In a trial of women receiving RT with or without tamoxifen following mastectomy, those receiving tamoxifen had a significant increase in the incidence of lung fibrosis (relative risk 2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/29\">",
"       29",
"      </a>",
"      ]. Tamoxifen is thought to induce TGF-beta secretion, which is a key factor in the signaling cascade leading to fibrosis. Tamoxifen may also increase the incidence of subcutaneous fibrosis when given concurrently with RT, but this has not been a consistent finding in all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In men, hormonal therapy given concurrently with RT for prostate cancer can increase the incidence of acute and late gastrointestinal and genitourinary toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/19,32-34\">",
"       19,32-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and assessment of severity of radiation-induced fibrosis depends upon the tissues involved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrosis of the skin and subcutaneous tissue is usually diagnosed by palpation and inspection. Radiation-induced fibrosis is limited to the volume treated with RT. To quantify the extent of radiation-induced fibrosis, the surface area and depth of involvement should be measured. This evaluation can be repeated to assess the potential effect of any therapeutic intervention.",
"     </li>",
"     <li>",
"      Endoscopy or imaging with contrast agents (eg, esophagograms) can be used to demonstrate the loss of elasticity of an organ wall as a result of radiation-induced fibrosis.",
"     </li>",
"     <li>",
"      Ultrasound may quantify the extent of radiation-induced fibrosis in the neck [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In other anatomic regions, functional tests (eg, for salivary gland function or nerve function in plexus lesions associated with radiation-induced fibrosis) might be helpful, but are non-specific for the diagnosis of radiation-induced fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Radiation Therapy Oncology Group has developed organ-specific classification systems that can be used to describe the severity of RT side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of radiation-induced fibrosis often includes recurrent tumor, and magnetic resonance imaging (MRI) may be useful in excluding this possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Persistent parenchymal enhancement after MRI contrast application is associated with fibrosis, although the extent of radiation-induced fibrosis cannot be assessed with this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies and other surgical interventions in areas with radiation fibrosis should be performed only when necessary to exclude tumor recurrence since wound healing may be impaired in previously irradiated areas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, surgery may result in a worsening of fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis can cause a wide range of clinical manifestations, including cutaneous induration, lymphedema, restrictions in joint motion, strictures and stenoses in hollow organs, and ulcerations. An overview of common manifestations of radiation-induced fibrosis in various organ systems and the associated clinical symptoms is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef78310 \" href=\"UTD.htm?22/58/23467\">",
"     table 1",
"    </a>",
"    ). Other radiation-induced fibrosis-related symptoms exist but are less frequent.",
"   </p>",
"   <p>",
"    Radiation-induced fibrosis typically presents 4 to 12 months after RT and progresses over several years. Although radiation-induced fibrosis can occur without acute symptoms during or immediately after RT, late toxicity often follows acute reactions in the same organ, either immediately or after a latency period.",
"   </p>",
"   <p>",
"    Late toxicities following acute effects are termed consequential late effects and are directly dependent upon the degree and duration of acute toxicities. Consequential late effects are well described for bladder, bowel, lung, skin and mucosal membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin and subcutaneous tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis of the skin and subcutaneous tissue is seen most commonly in breast cancer patients in areas with overlapping treatment fields following breast-conserving surgery with postoperative RT or after mastectomy and RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=see_link&amp;anchor=H22#H22\">",
"     \"Radiation techniques for locally advanced breast cancer\", section on 'Potential complications of radiation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=see_link\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for developing radiation-induced fibrosis after conventional RT for breast cancer is low, particularly with the use of modern skin-sparing megavoltage equipment. Signs and symptoms can include skin retraction and induration, pain, necrosis and ulceration, restricted arm and neck movement, lymphedema, and brachial or cervical plexopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/41\">",
"     41",
"    </a>",
"    ]. The risk for radiation-induced fibrosis is also low after brachytherapy alone and seems to depend on the maximum skin dose delivered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/15,42\">",
"     15,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"     \"Overview of cancer pain syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation-induced fibrosis of the chest wall has also been reported following stereotactic body radiation therapy for lung lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H5#H5\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Lung tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Head and neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trismus is a frequent late effect that occurs in 8 to 35 percent of head and neck cancer patients following RT, which is caused by inflammation and fibrosis in the muscles of mastication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/43\">",
"     43",
"    </a>",
"    ]. Radiation-induced fibrosis results in a loss of the ability to fully open the mouth, which can progress over time. The risk of radiation-induced fibrosis in the head and neck region is increased in patients who have had surgery, and in those treated with RT for recurrent tumor. In addition to trismus, RT can cause skin and subcutaneous fibrosis, resulting in induration and lymphedema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822571#H3822571\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Trismus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiation sensitivity of different parts of the gastrointestinal tract differs, with tolerance doses varying between 40 to 70 Gy. The manifestations of toxicity are dependent upon the area irradiated.",
"   </p>",
"   <p>",
"    Radiation-induced fibrosis in the esophagus may lead to strictures, ulcerations, and fistula formation. The risk of complications may be increased when RT is combined with chemotherapy, with up to 20 percent of patients developing strictures after combined modality treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late small bowel toxicity is more common after pelvic RT, with its higher doses of RT, rather than after abdominal irradiation. The incidence of radiation-induced fibrosis is low after pelvic RT doses of 50 Gy, whereas a 5 percent incidence of small bowel toxicity has been reported with pelvic irradiation to doses &gt;70 Gy for gynecologic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"     \"Diagnosis and management of chronic radiation enteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation-induced fibrosis of the rectum resulting in strictures occurs primarily in patients with cervix or prostate cancer when high curative doses of RT are used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Genitourinary tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced changes can affect the bladder, ureters, urethra, or vagina depending upon the site and dose of RT. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrotic constriction of the bladder can occur after doses of 65 to 70 Gy to small treatment volumes and after lower doses when the entire bladder is irradiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H9#H9\">",
"       \"Cystitis in patients with cancer\", section on 'Radiation cystitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ureteral strictures are rare, but occur in 1 to 3 percent of cases after gynecological treatment involving brachytherapy, which delivers high single doses to the distal ureters [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In men treated with 60 to 70 Gy for prostate cancer, the incidence of urethral strictures is 0 to 5 percent for those without a prior TURP and 5 to 15 percent with an antecedent TURP [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      External beam RT and brachytherapy for gynecologic tumors can cause radiation-induced fibrosis of the vulva and vagina with symptomatic shortening and narrowing of the vagina, dryness, and dyspareunia in up to 70 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/45\">",
"       45",
"      </a>",
"      ]. Symptoms may also be seen after RT for other pelvic tumors, if the female reproductive tract is included in the RT treatment fields.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiotherapy techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of radiation-induced fibrosis relies upon minimizing the dose and volume of normal tissue irradiated. With modern conformal RT techniques, high doses are delivered to the tumor while normal tissue should largely be spared [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Using these approaches, a long-term reduction in the incidence of radiation-induced fibrosis should be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplemental techniques that are helpful to avoid complications of RT include the use of equipment such as belly boards that minimize intestinal irradiation and thereby avoid small bowel toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/49\">",
"     49",
"    </a>",
"    ], treating patients with a full bladder to avoid intestinal sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/50\">",
"     50",
"    </a>",
"    ], and avoiding large single doses. Minimizing acute toxicity is thought to be important in reducing consequential late effects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of radiation-induced fibrosis depends upon the location and extent of the fibrosis, as well as the severity of symptoms. Therapeutic approaches include medical management of symptoms, conservative interventions such as dilatation and stent implantation for stenoses (eg esophagus, ureter), and surgical treatment of adhesions and strictures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients thought to be at high risk for radiation-induced fibrosis, early initiation of active and passive physical therapy measures is helpful.",
"     </li>",
"     <li>",
"      A special type of massage (\"LPG\") has been shown to reduce skin fibrosis after radiotherapy for breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In women receiving pelvic RT, regular vaginal dilatation and topical estrogen cream may be useful to prevent symptomatic shortening and narrowing of the vagina [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with early signs or symptoms of trismus, forced opening of the mouth is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preliminary results on the use of botulinum toxin type A for trismus, cervical dystonia and neuralgias associated with radiation-induced fibrosis were encouraging [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lymph drainage for lymph edema and physical therapy to treat articular contractions are other conservative ways that may ameliorate manifestations of late radiation-induced fibrosis.",
"     </li>",
"     <li>",
"      In a small study on patients with severe radiation-induced fibrosis after breast conserving therapy for breast cancer, partial mastectomy and m. latissimus dorsi reconstruction has been helpful to reduce symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adequate analgesic medication is important as well, since radiation-induced fibrosis can be painful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any surgical or mechanical intervention potentially can worsen the underlying fibrosis, thereby exacerbating symptoms. The risks of active interventions therefore need to be weighed against the possible benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. Although conservative approaches are favored, surgery may be required, particularly if a tumor recurrence cannot otherwise be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pentoxifylline plus tocopherol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    is a xanthine derivative that inhibits platelet aggregation and enhances microvascular blood flow. It has been used alone and in combination with tocopherol, both to prevent and treat radiation-induced fibrosis. Pentoxifylline may also inhibit fibroblast proliferation and the production of extracellular matrix, while tocopherol is a scavenger of reactive oxygen&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    was assessed for the prevention of radiation-induced fibrosis included 40 patients with either lung or breast cancer, who were receiving RT that included normal lung in the treatment field. Although there was a statistically significant benefit associated with pentoxifylline treatment, the activity of pentoxifylline to prevent pulmonary toxicity requires confirmation. The role of pentoxifylline in radiation-induced lung injury is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link&amp;anchor=H27#H27\">",
"     \"Radiation-induced lung injury\", section on 'Pentoxifylline'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential clinical utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , either alone or with tocopherol (vitamin E), to treat established radiation-induced fibrosis was initially suggested by case reports and observational series in a variety of settings, in which treatment resulted in healing or symptomatic improvement. These observations included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Partial reversal of soft tissue fibrosis following RT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/41,55-57\">",
"       41,55-57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Healing of radiation-induced soft tissue and bone necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improvement in symptoms of trismus [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduction in pelvic fibrosis after childhood RT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improvement of radiation-induced lumbosacral polyradiculopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple small randomized trials have suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    and or vitamin E may have a role in minimizing radiation fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/14,65-67\">",
"     14,65-67",
"    </a>",
"    ]. The two largest of these trials illustrate the potential utility of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 83 women with breast cancer were randomly assigned to treatment with vitamin E plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      or vitamin E plus placebo for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/65\">",
"       65",
"      </a>",
"      ]. Increase in arm volume was significantly greater in patients receiving vitamin E plus placebo rather vitamin E plus pentoxifylline. Arm abduction, which was significantly impaired at baseline, improved significantly in both groups; the improvement was greater in those receiving pentoxifylline although the difference was not statistically significant.",
"     </li>",
"     <li>",
"      In a second trial, 68 women with long-standing lymphedema of the arm following axillary surgery and radiotherapy were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      plus tocopherol or matched placebos for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/66\">",
"       66",
"      </a>",
"      ]. No effect was observed at 6 or 12 months in arm volume, or in secondary parameters including fibrosis of the breast, chest wall, and regional lymph node areas was seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More prolonged therapy may be an important factor in reversing the effects of radiation-induced fibrosis. In a detailed longitudinal series, regression of superficial radiation-induced fibrosis following irradiation for breast cancer was assessed in 44 women with 55 areas of superficial radiation-induced fibrosis during and after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus tocopherol (1000",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/1\">",
"     1",
"    </a>",
"    ]. Seven patients were treated for 6 to 12 months and therapy was then discontinued, while 37 patients remained on treatment for 24 to 48 months.",
"   </p>",
"   <p>",
"    Overall, the mean estimated maximal regression in surface area of radiation-induced fibrosis was 68 percent, and this regression required an average of 24 months of treatment. The time to maximum regression of radiation-induced fibrosis was shorter in patients with fibrosis of less than six years duration (16 months versus 28 months for those with fibrosis of longer duration). Among the seven patients who were treated for 6 to 12 months, a rebound increase in fibrotic area was observed after cessation of treatment.",
"   </p>",
"   <p>",
"    In summary, these data suggest that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    plus tocopherol can reverse superficial radiation-induced fibrosis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/68\">",
"     68",
"    </a>",
"    ]. The optimal dose and duration of therapy and the role of tocopherol are unknown. However, some data suggest that a prolonged course of treatment may be necessary to induce maximal regression of radiation-induced fibrosis and to maintain any benefit. These results require additional confirmation. Furthermore, it is not clear whether these results can be extrapolated to radiation-induced fibrosis in other tissues, or whether treatment with pentoxifylline plus tocopherol needs to be continued indefinitely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    may reduce the incidence and severity of the acute side effects from RT at various treatment sites.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple randomized clinical trials have evaluated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      for the prevention of xerostomia in patients receiving RT or chemoradiotherapy for head and neck cancer. These trials have given conflicting results, and the role of amifostine in this setting remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link&amp;anchor=H722454217#H722454217\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Amifostine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although an initial randomized trial showed benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      in patients receiving lung irradiation, a subsequent larger trial did not confirm these results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link&amp;anchor=H29#H29\">",
"       \"Radiation-induced lung injury\", section on 'Amifostine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one randomized trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"       amifostine",
"      </a>",
"      decreased the incidence of acute cystitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H17#H17\">",
"       \"Cystitis in patients with cancer\", section on 'Amifostine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    requires intravenous or subcutaneous administration and is associated with significant side effects. Amifostine has not been assessed for the treatment of established radiation-induced fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen has been evaluated as a treatment for radiation-induced fibrosis in at least three small studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two observational studies, which together included a total of 31 women, found that hyperbaric oxygen decreased lymphedema following surgery plus RT for breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. The observed benefit persisted for at least one year.",
"     </li>",
"     <li>",
"      A double-blind trial in 34 women treated for radiation-induced brachial plexopathy did not demonstrate any benefit from hyperbaric oxygen [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17129/abstract/71\">",
"       71",
"      </a>",
"      ]. However, two of the women who were treated with hyperbaric oxygen did have substantial improvement in their lymphedema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=see_link\">",
"       \"Overview of cancer pain syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there is insufficient evidence to indicate that hyperbaric oxygen can reverse radiation-induced fibrosis, although some effect cannot be ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced fibrosis can develop as a late effect in multiple tissues, as a function of the dose and volume of radiation, as well as the radiation sensitivity of a given tissue. Radiation-induced fibrosis may cause both cosmetic and functional impairment, which can lead to a significant deterioration in the quality of life or even death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary approach to the prevention of radiation-induced fibrosis is through the use of appropriate RT doses and techniques that minimize the radiation exposure for normal tissue. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Radiotherapy techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with established radiation-induced fibrosis, treatment is primarily symptomatic and depends upon the organ system involved. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Symptomatic treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with established, symptomatic subcutaneous fibrosis, we suggest a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      and tocopherol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The optimal duration of therapy is unknown, but treatment may be required for two or more years to observe and maintain any benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pentoxifylline plus tocopherol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/1\">",
"      Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005; 23:8570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/2\">",
"      Haase O, Rodemann HP. Fibrosis and cytokine mechanisms: relevant in hadron therapy? Radiother Oncol 2004; 73 Suppl 2:S144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/3\">",
"      Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/4\">",
"      Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/5\">",
"      Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/6\">",
"      Vozenin-Brotons MC, Milliat F, Sabourin JC, et al. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int J Radiat Oncol Biol Phys 2003; 56:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/7\">",
"      Yarnold J, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 2010; 97:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/8\">",
"      Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010; 174:865.",
"     </a>",
"    </li>",
"    <li>",
"     Herrmann T, Baumann M, D&ouml;rr W. Clinical Radiation Biology, Elsevier, Munich 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/10\">",
"      Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005; 75:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/11\">",
"      Geara FB, Komaki R, Tucker SL, et al. Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. Int J Radiat Oncol Biol Phys 1998; 41:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/12\">",
"      Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/13\">",
"      Collette S, Collette L, Budiharto T, et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer 2008; 44:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/14\">",
"      Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003; 21:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/15\">",
"      Cuttino LW, Heffernan J, Vera R, et al. Association between maximal skin dose and breast brachytherapy outcome: a proposal for more rigorous dosimetric constraints. Int J Radiat Oncol Biol Phys 2011; 81:e173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/16\">",
"      Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 1995; 31:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/17\">",
"      Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/18\">",
"      Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/19\">",
"      Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005; 61:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/20\">",
"      Andreassen CN, Overgaard J, Alsner J, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/21\">",
"      H&ouml;lscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol 2006; 78:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/22\">",
"      Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2007; 67:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/23\">",
"      Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/24\">",
"      Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999; 43:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/25\">",
"      Maruyama Y, Van Nagell JR Jr, Utley J, et al. Radiation and small bowel complications in cervical carcinoma therapy. Radiology 1974; 112:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/26\">",
"      Girinsky T, Cosset JM. [Pulmonary and cardiac late effects of ionizing radiations alone or combined with chemotherapy]. Cancer Radiother 1997; 1:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/27\">",
"      Toledano A, Garaud P, Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys 2006; 65:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/28\">",
"      Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003; 68:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/29\">",
"      Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/30\">",
"      Azria D, Gourgou S, Sozzi WJ, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 2004; 91:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/31\">",
"      Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995; 31:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/32\">",
"      Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002; 86:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/33\">",
"      Schultheiss TE, Hanks GE, Hunt MA, Lee WR. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/34\">",
"      Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 63:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/35\">",
"      Leung SF, Zheng Y, Choi CY, et al. Quantitative measurement of post-irradiation neck fibrosis based on the young modulus: description of a new method and clinical results. Cancer 2002; 95:656.",
"     </a>",
"    </li>",
"    <li>",
"     Radiation Therapy Oncology Group Common Toxicity Criteria file://www.rtog.org/ResearchAssociates/AdverseEventReporting/CooperativeGroupCommonToxicityCriteria.aspx (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/37\">",
"      Hoeller U, Bonacker M, Bajrovic A, et al. Radiation-induced plexopathy and fibrosis. Is magnetic resonance imaging the adequate diagnostic tool? Strahlenther Onkol 2004; 180:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/38\">",
"      Semiz Oysu A, Ayanoglu E, Kodalli N, et al. Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 2005; 29:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/39\">",
"      Padhani AR, Yarnold JR, Regan J, Husband JE. Magnetic resonance imaging of induration in the irradiated breast. Radiother Oncol 2002; 64:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/40\">",
"      D&ouml;rr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001; 61:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/41\">",
"      Delanian S, Balla-Mekias S, Lefaix JL. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol 1999; 17:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/42\">",
"      Strnad V, Hildebrandt G, P&ouml;tter R, et al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011; 80:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/43\">",
"      Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol 2006; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/44\">",
"      Perez CA, Fox S, Lockett MA, et al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: analysis of two different methods. Int J Radiat Oncol Biol Phys 1991; 21:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/45\">",
"      P&ouml;tter R, Knocke TH, Fellner C, et al. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother 2000; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/46\">",
"      Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003; 27:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/47\">",
"      Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002; 52:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/48\">",
"      McCormick B, Hunt M. Intensity-modulated radiation therapy for breast: is it for everyone? Semin Radiat Oncol 2011; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/49\">",
"      Martin J, Fitzpatrick K, Horan G, et al. Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study. Radiother Oncol 2005; 74:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/50\">",
"      Kim TH, Chie EK, Kim DY, et al. Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients. Int J Radiat Oncol Biol Phys 2005; 62:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/51\">",
"      Bourgeois JF, Gourgou S, Kramar A, et al. A randomized, prospective study using the LPG technique in treating radiation-induced skin fibrosis: clinical and profilometric analysis. Skin Res Technol 2008; 14:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/52\">",
"      PITKIN RM, BRADBURY JT. THE EFFECT OF TOPICAL ESTROGEN ON IRRADIATED VAGINAL EPITHELIUM. Am J Obstet Gynecol 1965; 92:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/53\">",
"      Stubblefield MD, Levine A, Custodio CM, Fitzpatrick T. The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. Arch Phys Med Rehabil 2008; 89:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/54\">",
"      van Geel AN, Lans TE, Haen R, et al. Partial mastectomy and m. latissimus dorsi reconstruction for radiation-induced fibrosis after breast-conserving cancer therapy. World J Surg 2011; 35:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/55\">",
"      Haddad P, Kalaghchi B, Amouzegar-Hashemi F. Pentoxifylline and vitamin E combination for superficial radiation-induced fibrosis: a phase II clinical trial. Radiother Oncol 2005; 77:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/56\">",
"      Okunieff P, Augustine E, Hicks JE, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004; 22:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/57\">",
"      Futran ND, Trotti A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations. Laryngoscope 1997; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/58\">",
"      Dion MW, Hussey DH, Doornbos JF, et al. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 1990; 19:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/59\">",
"      Delanian S, Depondt J, Lefaix JL. Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck 2005; 27:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/60\">",
"      Delanian S, Lefaix JL. Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. Br J Radiol 2002; 75:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/61\">",
"      Chua DT, Lo C, Yuen J, Foo YC. A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am J Clin Oncol 2001; 24:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/62\">",
"      Letur-K&ouml;nirsch H, Guis F, Delanian S. Uterine restoration by radiation sequelae regression with combined pentoxifylline-tocopherol: a phase II study. Fertil Steril 2002; 77:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/63\">",
"      Gothard L, Cornes P, Brooker S, et al. Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol 2005; 75:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/64\">",
"      Delanian S, Lefaix JL, Maisonobe T, et al. Significant clinical improvement in radiation-induced lumbosacral polyradiculopathy by a treatment combining pentoxifylline, tocopherol, and clodronate (Pentoclo). J Neurol Sci 2008; 275:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/65\">",
"      Magnusson M, H&ouml;glund P, Johansson K, et al. Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: a phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5). Eur J Cancer 2009; 45:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/66\">",
"      Gothard L, Cornes P, Earl J, et al. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 2004; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/67\">",
"      Jacobson G, Bhatia S, Smith BJ, et al. Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys 2013; 85:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/68\">",
"      Anscher MS. The irreversibility of radiation-induced fibrosis: fact or folklore? J Clin Oncol 2005; 23:8551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/69\">",
"      Gothard L, Stanton A, MacLaren J, et al. Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol 2004; 70:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/70\">",
"      Teas J, Cunningham JE, Cone L, et al. Can hyperbaric oxygen therapy reduce breast cancer treatment-related lymphedema? A pilot study. J Womens Health (Larchmt) 2004; 13:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17129/abstract/71\">",
"      Pritchard J, Anand P, Broome J, et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 2001; 58:279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7055 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17129=[""].join("\n");
var outline_f16_46_17129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RT parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin and subcutaneous tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiotherapy techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pentoxifylline plus tocopherol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Amifostine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/58/23467\" title=\"table 1\">",
"      Clin manif RT fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=related_link\">",
"      Diagnosis and management of chronic radiation enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21146?source=related_link\">",
"      Overview of cancer pain syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17130="Anti-IgE therapy";
var content_f16_46_17130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anti-IgE therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/46/17130/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/46/17130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin E (IgE) plays a central role in the pathogenesis of allergic diseases, including asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/1\">",
"     1",
"    </a>",
"    ]. For this reason, IgE-mediated immunologic pathways have long represented an attractive target for therapeutic agents in asthma.",
"   </p>",
"   <p>",
"    This review will examine IgE neutralization therapy with anti-IgE monoclonal antibody for the treatment of asthma. This biologic therapy neutralizes IgE by preventing its binding to IgE receptors. Other promising approaches to reducing IgE, as well as investigational applications of anti-IgE to other disorders will be discussed briefly. The role of anti-IgE therapy in the overall management of asthma, as recommended by national and international asthma guidelines, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ROLE OF IgE IN ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most asthmatic patients have elevated circulating IgE concentrations when levels are adjusted for age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/2\">",
"     2",
"    </a>",
"    ]. Allergic sensitization results from the formation of specific IgE in response to common inhalant allergens, such as those derived from house dust mites, pollens, animal dander, molds, and cockroaches.",
"   </p>",
"   <p>",
"    IgE is produced by B lymphocytes under the direction of two cytokines: interleukin (IL)-4 and the closely related IL-13, which are produced by several cell types, including Th2 cells, a subset of T-helper lymphocytes prevalent in atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. IgE formation is markedly enhanced by the interaction of two costimulatory molecules: CD40 ligand expressed on Th2 cells and CD40 expressed on B cells. Appropriately stimulated B cells mature into plasma cells that secrete allergen-specific IgE, which circulates and binds to high affinity receptors (Fc&epsilon;RI) on the surface of mast cells, basophils, and other cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link&amp;anchor=H3#H3\">",
"     \"Mast cells: Surface receptors and signal transduction\", section on 'High affinity IgE receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cross-bridging of these IgE molecules on mast cells and basophils by protein allergens results in their activation, with release of preformed mediators such as histamine, and increased synthesis of lipid mediators such as prostaglandins and cysteinyl-leukotrienes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/5\">",
"     5",
"    </a>",
"    ]. Release of mast cell mediators results in bronchoconstriction and plasma exudation. Thus, IgE plays a central role in the mechanism of immediate bronchoconstriction in allergic asthmatic patients after inhalation of allergen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=see_link\">",
"     \"The biology of IgE\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating IgE also binds to high affinity receptors on dendritic cells, and to low affinity IgE receptors (Fc&epsilon;RII or CD23), found on B-lymphocytes, monocytes, macrophages, and dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/6\">",
"     6",
"    </a>",
"    ]. Allergen may also interact with bound IgE on these cells, although higher concentrations of allergenic proteins may be required to result in cell activation.",
"   </p>",
"   <p>",
"    Atopy is the strongest risk factor for developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. Up to 80 percent of asthmatic patients in the United States and other developed countries are atopic, with one or more positive skin tests to common allergens and detectable allergen-specific IgE concentrations in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A small proportion of asthmatic patients have \"intrinsic\" asthma with negative skin tests, normal levels of total IgE, and no circulating specific IgE. However, some of these patients may have local mucosal formation of IgE or may have IgE directed against currently unrecognized environmental allergens, suggesting that IgE may be abnormal in nearly all asthmatic patients, irrespective of whether they are atopic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effects of other therapies on IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids do not inhibit IgE synthesis by B lymphocytes and may even increase circulating IgE by enhancing the expression of CD40 ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunotherapy is not considered first-line therapy for the majority of patients with asthma, and injection immunotherapy is associated with significant risk of systemic reactions in those with moderate to severe persistent asthma. However, immunotherapy should be considered in some atopic patients with clear allergic triggers. Successful immunotherapy is associated with a suppression of the usual postseasonal rise in allergen-specific IgE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765588\">",
"    <span class=\"h1\">",
"     OMALIZUMAB THERAPY IN ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    is a recombinant humanized IgG1 monoclonal antibody that binds IgE with high affinity and has been developed for the treatment of allergic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. At the time of this review, omalizumab is the only available anti-IgE therapy in use. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Other novel strategies to reduce IgE'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7764932\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States and many other countries where it is available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    is approved for use in patients with ALL of the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twelve years of age and older",
"     </li>",
"     <li>",
"      Moderate to severe persistent asthma",
"     </li>",
"     <li>",
"      Asthma symptoms that are inadequately controlled with inhaled glucocorticoids (in the United Kingdom, patients must have symptoms despite high doses of inhaled glucocorticoids)",
"     </li>",
"     <li>",
"      A total serum IgE level between 30 and 700 international",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      <span class=\"nowrap\">",
"       (IU/mL),",
"      </span>",
"      which is the range over which the drug can bind to enough free IgE to ensure a therapeutic effect (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanisms of action'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Allergic sensitization demonstrated by positive skin testing or in vitro testing for allergen-specific IgE to an allergen that is present year round (a perennial allergen), such as dust mite, animal danders, cockroach, or molds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007 National Asthma Education and Prevention Program (NAEPP) asthma guidelines recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    be considered as adjunctive therapy in step 5 or 6 care for patients with allergies and severe persistent asthma (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the future, the manufacturer is expected to seek approval for children 6 to 11 years of age, and trials including younger children showed similar efficacy in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    has not been approved for use in other allergic diseases or patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765369\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who meet all the criteria for approved use, there are limited characteristics that predict a positive response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    . In a randomized trial of 1070 patients with allergic asthma performed to assess clinical predictors of responsiveness to omalizumab, only impaired baseline lung function and frequent exacerbations despite high dose inhaled glucocorticoid therapy were correlated to a good response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of allergic triggers in a patient&rsquo;s disease may be a factor, although the best means of assessing this beyond clinical history has not been determined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 419 inner city children, adolescents, and young adults (6 to 20 years of age) found the greatest benefit in patients with allergy to prevalent indoor allergens (cockroach and dust mite) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/22\">",
"       22",
"      </a>",
"      ]. Unexpectedly, this study also found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      reduced seasonal exacerbations in the fall and spring, without altering rates of positive cultures for common respiratory viruses. These findings indicate that, as would be expected, omalizumab does not prevent viral infection, although it may have some indirect effect on the patient&rsquo;s tendency to develop an asthma exacerbation as a result of that infection. Alternatively, it may provide some protective benefit based on its effects on seasonal allergic triggers. These issues require further study.",
"     </li>",
"     <li>",
"      Preliminary data suggests that patients with low total IgE (ie, below 30",
"      <span class=\"nowrap\">",
"       IU/mL),",
"      </span>",
"      who have a relatively high proportion of allergen-specific IgE, also respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. However, this subgroup of patients requires further study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765376\">",
"    <span class=\"h3\">",
"     Occupational asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    has been reported to ameliorate occupational asthma in patients who are unable to change their work environment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14489?source=see_link&amp;anchor=H293008290#H293008290\">",
"     \"Occupational asthma: Management, prognosis, and prevention\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanisms of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    binds to the third constant domain of the IgE heavy chain (C&epsilon;3), which is the same site at which IgE normally binds to both high and low affinity IgE receptors on mast cells, basophils, and other cell types. Thus, omalizumab forms complexes with free IgE and prevents its interaction with these receptors. The omalizumab-IgE complexes are subsequently cleared by the hepatic reticuloendothelial system (",
"    <a class=\"graphic graphic_figure graphicRef59320 \" href=\"UTD.htm?32/26/33191\">",
"     figure 2",
"    </a>",
"    ). The antibody is specific to IgE and does not bind to IgG or IgA. An important property of omalizumab is that it cannot bind to IgE receptors or to IgE already attached to Fc&epsilon;RI, and therefore does not interact with cell-bound IgE or activate mast cells or basophils by interacting with Fc&epsilon;RI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Hypersensitivity reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Free IgE must be reduced to extremely low levels to achieve clinical efficacy. This is because there are 10,000 to 1,000,000 Fc&epsilon;RI on mast cells and basophils and nearly all are occupied by IgE. Only 2000 IgE molecules are needed for half-maximal release of histamine from basophils; therefore, a marked reduction in IgE is needed to prevent mast cell and basophil activation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/29\">",
"     29",
"    </a>",
"    ]. In one study of atopic subjects, free IgE dropped after each twice-weekly dose down to concentrations that were 1 percent of the starting IgE level.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    therapy causes a marked downregulation of Fc&epsilon;RI on the surface of basophils and mast cells, although the time course of this change may differ in the two cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of ragweed-allergic patients with allergic rhinitis, Fc&epsilon;RI on the surface of basophils was reduced by 73 percent after seven days of treatment and correlated with a decreased clinical response to allergen on nasal challenge [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the downregulation of receptors on cutaneous mast cells occurs more slowly. In a study of dust mite-allergic patients with allergic rhinitis, the expression of Fc&epsilon;RI on cutaneous mast cells was unchanged after seven days of treatment, but 90 percent reduced at 70 days [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/32\">",
"       32",
"      </a>",
"      ]. The number of cells staining positive for tryptase was unchanged, demonstrating that the mast cells were still present but receptor expression had decreased. These mast cell changes correlate to a gradual reduction in cutaneous skin test responses [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/32,37\">",
"       32,37",
"      </a>",
"      ]. A decrement in the late-phase cutaneous response is seen by two weeks, followed by a decrease in the early phase at eight weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    on nonspecific airway hyperresponsiveness is not well-defined. Omalizumab given intravenously, twice weekly for 10 weeks, had a small effect upon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    reactivity in one study of mild asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/39\">",
"     39",
"    </a>",
"    ]. In a later study of 16 weeks of therapy in mild to moderate asthma, there were no significant changes in methacholine responsiveness in the omalizumab or placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is usually no improvement in forced expiratory volume in the first second (FEV1) when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    is added to pre-existing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have demonstrated antiinflammatory effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/40,43-45\">",
"     40,43-45",
"    </a>",
"    ]. In the 16 week study mentioned previously, markers of airway inflammation were significantly reduced after the course of therapy, as assessed in induced sputum and bronchial biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/40\">",
"     40",
"    </a>",
"    ]. Omalizumab-treated patients showed reductions in sputum eosinophil counts (from 7 to 2 percent), decreased eosinophils in biopsy, and reduced numbers of CD3+, CD4+, and CD8+ T lymphocytes, B lymphocytes, and IL-4 positive cells. IgE positive cells in the bronchial mucosa were decreased 10-fold.",
"   </p>",
"   <p>",
"    Other effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    include a reduction in the number of lymphocytes expressing IL-2, IL-13, or GM-CSF, although the mechanisms involved and the interrelationship of these findings requires further study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/46\">",
"     46",
"    </a>",
"    ]. The drug also reduces Fc&epsilon;RI mediated production of Th2 cytokines by basophils [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with moderate to severe asthma, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    (compared to placebo) can result in a significant reduction in the dose of inhaled or oral glucocorticoids required to control symptoms and can decrease the incidence of exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/43,44,48,49\">",
"     43,44,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7599108\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an example, two multicenter trials, which together included over 1000 patients, randomly assigned patients with moderate to severe asthma to treatment with placebo or injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    (0.016",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of IgE per month) using a very similar study design (",
"    <a class=\"graphic graphic_figure graphicRef71216 \" href=\"UTD.htm?14/25/14750\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. After four to six weeks of inhaled glucocorticoid optimization, patients received the active treatment for a period of 28 weeks. No changes were made to their inhaled glucocorticoid dosing during the first 16 weeks (stable-steroid phase), although for the next 12 weeks, they underwent an active, symptom-limited, dose reduction protocol (steroid-withdrawal phase). When results of the two studies were pooled, treatment with omalizumab was associated with the following significant improvements (",
"    <a class=\"graphic graphic_figure graphicRef72697 \" href=\"UTD.htm?18/15/18687\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81434 \" href=\"UTD.htm?26/8/26766\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Larger median dose reduction in inhaled glucocorticoids (83 versus 50 percent)",
"     </li>",
"     <li>",
"      Higher percentage of patients able to discontinue inhaled glucocorticoids (43 versus 19 percent)",
"     </li>",
"     <li>",
"      Fewer exacerbations during both the stable-steroid (13 versus 31 percent) and steroid-withdrawal phases (16 versus 30 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent reports have confirmed these earlier findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/41,50-52\">",
"     41,50-52",
"    </a>",
"    ]. A 2011 systematic review included eight trials and 3429 patients treated with subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    (0.016",
"    <span class=\"nowrap\">",
"     mg/kg/IU/mL",
"    </span>",
"    of IgE every two to four weeks) as add-on therapy to inhaled and oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/42\">",
"     42",
"    </a>",
"    ]. Two of the trials were pediatric studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/49,53\">",
"     49,53",
"    </a>",
"    ], and all patients had moderate to severe allergic asthma. Compared to patients receiving placebo, those receiving omalizumab were [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More likely to be able to reduce their dose of inhaled glucocorticoid by 50 percent or more (RR = 1.3, 95% CI 1.2-1.5), with a median reduction in daily dose of approximately 141 micrograms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"     </li>",
"     <li>",
"      More likely to be able to discontinue inhaled glucocorticoids entirely (RR =1.8, 95% CI 1.4-2.3)",
"     </li>",
"     <li>",
"      Less likely to experience an asthma exacerbation (RR = 0.55, 95% CI 0.47-0.64)",
"     </li>",
"     <li>",
"      Less likely to be hospitalized for asthma (RR = 0.14, 95% CI 0.03-0.66)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7766019\">",
"    <span class=\"h3\">",
"     Patients with severe asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    in the treatment of severe asthma (rather than moderate to severe) was demonstrated in a subsequent randomized trial of 850 patients (aged 12 to 75 years) with uncontrolled symptoms despite both high-dose inhaled glucocorticoids (ie, doses &ge;500 &micro;g",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    twice daily) and LABA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/54\">",
"     54",
"    </a>",
"    ]. All patients had IgE levels within the specified range and sensitization to a perennial allergen. Treatment with omalizumab or placebo was administered for 12 months, during which other controller therapies were not changed. The primary endpoint was number of exacerbations requiring systemic glucocorticoids for more than three days, or requiring an increase in daily dose of &ge;20 mg for patients on chronic oral glucocorticoids. The rates of exacerbations per subject were 0.66 and 0.88 in the omalizumab and placebo groups, respectively, which corresponded to a 25 percent reduction in the incidence rate. The difference was statistically significant. Recommendations for the treatment of severe asthma are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study of patients with severe asthma was performed in 34 children, half of whom were 5 to 11 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/55\">",
"     55",
"    </a>",
"    ]. In this prospective, nonrandomized trial, consecutive children were chosen to receive four months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy if they required daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    during the preceding three months. Allergy testing was not performed. Baseline serum IgE levels ranged from 119 to 1193",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (note that the higher values are outside the range recommended by the manufacturer) with a median of 411",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"    Primary endpoints were reduction in prednisolone dose, and changes in quality of life, Childhood Asthma Control Test (ACT), and FEV1. After four months of treatment during which all other therapies were kept constant, 85 percent of the children were able to reduce their doses of prednisolone, with a median dose reduction from 20 mg to 5 mg daily. Dramatic reductions were seen in about 20 percent of subjects. Quality of life and ACT scores improved significantly. However, the lack of a placebo group and small size limit the conclusions that can be drawn from this study, and controlled trials are needed. Omalizumab is not approved for use in children younger than 12 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7599115\">",
"    <span class=\"h3\">",
"     Impact on acute allergen exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter study evaluated the effect of 16 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    treatment on 68 patients acutely exposed to high levels of allergen in the form of a cat chamber challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/56\">",
"     56",
"    </a>",
"    ]. Subjects were cat-allergic adults with moderate asthma and a history of cat-induced exacerbations, taking a mean daily dose of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    of 340 to 380 mcg. They were randomized to omalizumab therapy or placebo, and challenged in the chamber at week 0 and week 16. The primary endpoint was the area under the curve (AUC) of the percentage decrease from prechallenge FEV1 per hour of exposure. Patients receiving omalizumab demonstrated a significantly smaller reduction in FEV1 compared with those receiving placebo (15 versus 27 percent). Both chest and nasal symptoms were also significantly lower in the treatment group, and treated patients tolerated a median of 50 minutes in the chamber, compared to 22 minutes in the placebo group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    is administered by subcutaneous injection every two to four weeks in a dose that is determined by body weight and the levels of serum IgE (0.016",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of IgE per month) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/57\">",
"     57",
"    </a>",
"    ]. It should",
"    <strong>",
"     not",
"    </strong>",
"    be initiated in the setting of an acute exacerbation of asthma, nor should it be self-administered.",
"   </p>",
"   <p>",
"    Therapy requires a dose of 150 to 375 mg injected subcutaneously every two to four weeks. Peak serum concentration is reached in seven to eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/19\">",
"     19",
"    </a>",
"    ]. No more than 150 mg should be administered at a single site, to prevent local reactions. The elimination half-life of the drug is one to four weeks after subcutaneous administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pretreatment testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total serum IgE levels should be between 30 and 700 international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (IU/mL),",
"    </span>",
"    although case reports describe benefit in patients with IgE levels below and above this range [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. For patients with serum IgE levels above 300",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    there are upper limits of body weight beyond which administration is not recommended. Sensitization to a perennial aeroallergen (eg, dust mite, animal danders, cockroach, molds) must be demonstrated by positive skin testing or in vitro IgE testing. Baseline FEV1, peak flow, or other pulmonary function testing is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765170\">",
"    <span class=\"h3\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    is approved for administration by subcutaneous injection. Initial trials demonstrated that aerosolized omalizumab was ineffective in protecting against allergen challenge and had no effect on circulating IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/60\">",
"     60",
"    </a>",
"    ]. In contrast, parenteral use of the antibody significantly reduced the concentration of circulating free IgE and affected markers of asthma severity. In human subjects with atopy, intravenous omalizumab induced a rapid and sustained fall in free serum IgE of 96 percent following a 100 mg dose, with a mean recovery of 50 percent by 39 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/61\">",
"     61",
"    </a>",
"    ]. In one study with doses ranging from 0.0005 to 0.14",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously or 0.05 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, free IgE levels in plasma decreased in a dose-dependent fashion in both adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Thus, the subcutaneously route of delivery was chosen for practical reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765129\">",
"    <span class=\"h3\">",
"     Time to effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minimum of 12 weeks of treatment is needed to determine the efficacy of anti-IgE therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/23\">",
"     23",
"    </a>",
"    ]. A three to six month trial is appropriate. Some patients may respond only after months of treatment, but this appears to be atypical [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Monitoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific laboratories are suggested for monitoring patients who are responding clinically to anti-IgE therapy. Total serum IgE levels increase three to sixfold in all individuals on therapy (due to the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    : IgE immune complexes) and are not useful for monitoring clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/11,44,65\">",
"     11,44,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergen skin testing responses are significantly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/38\">",
"     38",
"    </a>",
"    ]. Free serum IgE levels decrease dramatically, although measurement of free IgE is not available outside of research settings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/66\">",
"     66",
"    </a>",
"    ]. One study found that free serum IgE levels did not predict clinical response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/67\">",
"     67",
"    </a>",
"    ]. Therapy may also interfere with the performance of most allergen-specific IgE assays, although the ImmunoCAP system (Phadia) appears to retain accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765080\">",
"    <span class=\"h3\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy in patients who experience clinical benefit has not been determined. Patients who respond are generally continued on the drug long-term. Long-term dosing should be adjusted for changes in body weight. Reductions in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    dose below the recommended formula (0.016",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of IgE per month) are likely to result in a loss of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy is discontinued, serum free IgE levels and skin test responses gradually return to baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There does not appear to be a noticeable \"rebound\" phenomenon when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy is stopped. In contrast, preliminary data suggest that there may be persistent benefit after the drug is discontinued. A report of 18 patients treated with omalizumab for six years found that the benefits of therapy were still detectable up to three years after discontinuation. In this study, 12 of 18 patients reported that their asthma was improved or unchanged compared to when they were actively receiving the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765756\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost is $10,000 to $12,000 per year for patients who require one vial (150 mg) every four weeks (the minimum dose), and incrementally higher for those requiring more, which far exceeds that of other approved asthma therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/18,19,71\">",
"     18,19,71",
"    </a>",
"    ]. Several analyses have questioned the cost-effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. On the other hand, a few centers have concluded that omalizumab has a favorable cost to utility ratio adult cohorts with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Information about cost for healthcare providers and patients is available at 1-866-4-XOLAIR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, all studies have indicated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    is generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/49,76,77\">",
"     49,76,77",
"    </a>",
"    ]. However, there are case reports and series of adverse reactions, including the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    include anaphylaxis, urticaria, and injection site reactions:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7766245\">",
"    <span class=\"h3\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis and anaphylactoid reactions that could not be ascribed to any other agent developed in approximately 1 to 2 in 1000 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. This rate of reaction is among the lowest of all biologicals currently on the market. However, a boxed warning was added to the package insert in 2007 at the recommendation of the United States Food and Drug Administration (FDA). The mechanism(s) in these reactions is not known, although a hypersensitivity reaction to the additive polysorbate 20 was implicated in a report of two cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anaphylaxis after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    may occur after any dose. In a review of 124 cases, 39 percent occurred with the first dose, and 19 percent, with the second dose. The reaction occurred after one of the first three doses in 68 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/79\">",
"     79",
"    </a>",
"    ]. Approximately 70 percent of reported cases occurred within two hours of administration, although anaphylactic events beginning as late four days after the injection and protracted anaphylaxis occurring over the course of one to two days have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    can be performed to evaluate apparent anaphylaxis to the drug. The drug should be diluted in normal saline. Prick testing can be performed with undiluted drug and a concentration of 1:100,000 (1.2",
"    <span class=\"nowrap\">",
"     micrograms/mL),",
"    </span>",
"    has been determined to be nonirritating for intradermal testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Recommended precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A joint task force of the American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology convened in 2007 to review the clinical trials and postmarketing surveillance data regarding anaphylaxis associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    . Their report included the following recommendations for clinicians prescribing omalizumab, which could be modified at the clinician's discretion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/80\">",
"     80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain informed consent from the patient after discussing the risks, benefits, and alternatives to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Educate the patient about the signs, symptoms, and treatment of anaphylaxis.",
"     </li>",
"     <li>",
"      Prescribe an epinephrine autoinjector(s) and instruct the patient on how and when to use it. Advise the patient to bring the autoinjector to every scheduled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      injection and carry it for at least 24 hours afterwards.",
"     </li>",
"     <li>",
"      Assess the patient's interim health status and pulmonary function prior to each injection and withhold",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      if the patient's status might place them at higher risk for a more serious outcome should anaphylaxis occur (eg, an active asthma exacerbation).",
"     </li>",
"     <li>",
"      Observe the patient for two hours after each of the first three injections, and for 30 minutes after each subsequent injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28924393\">",
"    <span class=\"h4\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    -associated allergic reactions have been desensitized. One report describes a protocol performed successfully in three patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/86\">",
"     86",
"    </a>",
"    ]. In another report, the patient initially tolerated omalizumab but later developed serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7766260\">",
"    <span class=\"h3\">",
"     Urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria has been reported to develop in approximately 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/83\">",
"     83",
"    </a>",
"    ]. The relationship between this limited reaction and risk for anaphylaxis has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Injection site reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection site reactions appeared with equal frequency in approximately 44 percent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    and placebo treated patients. These were mostly described as mild to moderate and ranged in size from 1.5 to 3 cm. Most local reactions occurred within one hour of injection and lasted for 3 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Serum sickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of case reports describe serum sickness-like reactions following administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. One case proved fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other issues that have arisen with continued use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    therapy include uncertain associations with increased rates of malignancies and the development of Churg-Strauss syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Unclear association with cardiovascular disease",
"      </strong>",
"      &mdash; An FDA interim safety analysis performed in 2009 of the Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS) trial, reported that there was an apparent increase among certain cardiovascular disorders in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      compared to the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/89\">",
"       89",
"      </a>",
"      ]. These disorders included ischemic heart disease, cardiomyopathy, arrhythmias, and embolic and thrombotic events. The FDA did not suggest stopping the drug and did not alter the prescribing information.",
"     </li>",
"     <li>",
"      <strong>",
"       Churg-Strauss syndrome",
"      </strong>",
"      &mdash; Cases of Churg-Strauss syndrome developing in temporal relationship with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      have been reported, although the coincident reduction in glucocorticoid therapy must also be considered as a possible contributing factor in expression of the disease. Reports about this association are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Omalizumab'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Omalizumab has also been administered as an investigational therapy for the treatment of Churg-Strauss syndrome. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Anti-IgE therapy in other diseases'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Susceptibility to parasitic infection",
"      </strong>",
"      &mdash; Concerns that reducing IgE might impair immunity to parasitic infections were addressed experimentally in mice infected with Nippostrongylus and Schistosoma; surprisingly, animals treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      showed increased rather than decreased elimination of parasites [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/90\">",
"       90",
"      </a>",
"      ]. However, a randomized trial of 137 people with allergic asthma who were at high risk for helminth infection and received omalizumab or placebo for one year, found a trend toward more infections in the omalizumab subjects, although the difference was not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/91\">",
"       91",
"      </a>",
"      ]. Thus, this issue warrants further investigation.",
"     </li>",
"     <li>",
"      <strong>",
"       Malignancy",
"      </strong>",
"      &mdash; Early data raised the possibility of an association between",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      treatment and malignancy, although this now seems unlikely. The manufacturer submitted an initial report to the FDA in 2003 of adverse effects in all preclinical and clinical studies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. This reported that there were 16 malignancies (0.4 percent) in the omalizumab group and 2 (0.1 percent) in the control group, representing a 0.3 percentage point increase in the rate of malignancy per year. These were largely solid tumors that varied in location and cell-type.",
"      <br/>",
"      <br/>",
"      A subsequent systematic review of 32 randomized trials identified 14 malignancies in 4254 omalizumab-treated patients and 11 in 3178 placebo-treated patients. No patterns in the type or histologic characteristics were detected, making it unlikely that there is an increased risk of malignancy with omalizumab treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Theoretical concerns",
"      </strong>",
"      &mdash; There are theoretical concerns about the therapy that have",
"      <strong>",
"       not",
"      </strong>",
"      been observed with clinical use. These include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thrombocytopenia was noted in experiments in which cynomolgus monkeys received 3 to 27 times the maximum human clinical dose, but has not been a significant problem in reported human trials to date [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Loss of effect with continued treatment has not been observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Safety in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding safety in pregnancy are limited and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    in pregnant women is not recommended. In a 2009 review of completed studies of omalizumab therapy, 47 pregnancies had been reported among female participants, 27 of whom were receiving the active drug. Outcomes were not different from those in women receiving placebo and other standard asthma therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ANTI-IgE THERAPY IN OTHER DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE plays a critical role in other allergic diseases, and it might be expected that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    may be beneficial in the treatment of allergic rhinitis, food allergy, chronic urticaria, and atopic dermatitis, although the use of omalizumab in disorders other than asthma is not currently approved by most drug regulatory bodies. As patients with nonallergic (intrinsic) asthma also have local IgE synthesis in the airways, it is possible that omalizumab may be beneficial in these patients, although studies in nonatopic asthma have yet been reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      is effective in reducing symptoms and the use of concomitant antihistamine therapy in seasonal rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/93-96\">",
"       93-96",
"      </a>",
"      ]. The beneficial effect is directly related to the reduction in free circulating IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/97\">",
"       97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"       \"Pharmacotherapy of allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several reports have described the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      prior to, or concomitant with, subcutaneous allergen immunotherapy. Omalizumab has been administered in this manner for the purpose of reducing systemic allergic reactions to the injections in patients who were otherwise unable to tolerate immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/98,99\">",
"       98,99",
"      </a>",
"      ], performing rapid desensitization protocols with fewer systemic reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/100\">",
"       100",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to enhance the beneficial effects of immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/101\">",
"       101",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=see_link&amp;anchor=H16#H16\">",
"       \"Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring\", section on 'Systemic reactions to VIT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies have explored the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      and related anti-IgE antibodies for the treatment of food allergy, nasal polyposis, bullous pemphigoid, asthma associated with Churg-Strauss syndrome, and aspergillosis-related pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/102-107\">",
"       102-107",
"      </a>",
"      ]. Dosing in these disorders may not conform to approved standards, since some patients have extremely high IgE levels that do not fall within the ranges for current recommended and approved dosing.",
"     </li>",
"     <li>",
"      Studies evaluating the effectiveness of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      for chronic urticaria refractory to other therapies and for some forms of physical urticaria are reviewed separately (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=see_link&amp;anchor=H19#H19\">",
"       \"Chronic urticaria: Treatment of refractory symptoms\", section on 'Omalizumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link&amp;anchor=H11#H11\">",
"       \"Cold urticaria\", section on 'Other pharmacotherapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"       \"Physical urticarias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      has been used to treat anaphylaxis in patients with mastocytosis and mast cell activation disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment and prognosis of systemic mastocytosis\", section on 'Additional symptom-specific treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Case reports and series of adult and pediatric patients with atopic dermatitis treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      have been mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/108-112\">",
"       108-112",
"      </a>",
"      ]. A systematic review suggested that there may be specific types of patients that are more responsive than others [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/113\">",
"       113",
"      </a>",
"      ]. A subsequent randomized trial of 20 patients found that treatment did not significantly alter several measures of disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/114\">",
"       114",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of atopic dermatitis (eczema)\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER NOVEL STRATEGIES TO REDUCE IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapeutic approaches to reduce IgE concentrations or effects are in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Anti-CD23",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD23 is the low affinity IgE receptor (Fc&epsilon;RII), which is present on the surface of many cell types, including B lymphocytes, monocytes, macrophages, and dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/115\">",
"     115",
"    </a>",
"    ]. CD23 is instrumental in multiple aspects of the allergic response, such as IgE-mediated antigen presentation, regulation of IgE synthesis, and differentiation of B and T cells. A monoclonal antibody to CD23 has been developed, and was shown to decrease serum total IgE in patients with allergic asthma in a phase I, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cytokine modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE synthesis is suppressed by inhibition of the cytokines IL-4 or IL-13, which are needed for class switching. IgE production is also inhibited by the cytokines interferon-gamma and IL-12, which switch the balance from Th2 towards Th1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/4\">",
"     4",
"    </a>",
"    ]. Several efforts have been made to influence IgE production at these upstream steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soluble human recombinant IL-4 receptor (altrakincept) given by inhalation has some steroid-sparing effect in asthma, although it failed in pivotal clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/117,118\">",
"       117,118",
"      </a>",
"      ]. Anti-IL-4 antibody therapy also failed in clinical trials. Neither had significant effects on serum IgE levels.",
"     </li>",
"     <li>",
"      Therapies targeting IL-13 and its receptor have also been studied:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A mutated IL-4 protein that blocks the common receptor for IL-4 and IL-13 (pitrakinra) significantly reduced the late response to inhaled allergen in patients with mild asthma, when given either by subcutaneous injection or by inhalation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, patients with severe asthma not controlled with high doses of inhaled glucocorticoids were treated with blocking antibody to IL-13 (lebrikizumab) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/120\">",
"       120",
"      </a>",
"      ]. Treatment resulted in a small but statistically significant improvement (~5 percent compared to placebo) at 12 weeks but not at 24 weeks, with no improvement in symptoms, asthma-related health status, or reduction in exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/120\">",
"       120",
"      </a>",
"      ]. IgE levels were not significantly reduced by this therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H9#H9\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Immune modulatory therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-12 reduces circulating eosinophils in asthma, presumably via an inhibitory effect on IL-5 production by Th2 cells, but the effect on circulating IgE is not known [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/121\">",
"       121",
"      </a>",
"      ]. However, this treatment is not well tolerated and is not being actively developed as a therapy.",
"     </li>",
"     <li>",
"      Interferon-gamma does not appear to be effective in the treatment of asthma, at least when given by inhalation, and its effects on IgE are not known [",
"      <a class=\"abstract\" href=\"UTD.htm?16/46/17130/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most asthmatic patients are atopic and have elevated circulating IgE concentrations when levels are adjusted for age. IgE plays a central role in the mechanism of immediate bronchoconstriction in allergic asthmatic patients after inhalation of allergen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Role of IgE in asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      is a recombinant humanized IgG1 monoclonal antibody that binds circulating IgE, forming immune complexes that are subsequently cleared by the hepatic reticuloendothelial system (",
"      <a class=\"graphic graphic_figure graphicRef59320 \" href=\"UTD.htm?32/26/33191\">",
"       figure 2",
"      </a>",
"      ). This binding inhibits the attachment of IgE to IgE receptors on mast cells, basophils, and other cell types, thereby reducing surface IgE receptor levels and the ability of these cells to be activated by allergens. (See",
"      <a class=\"local\" href=\"#H7765588\">",
"       'Omalizumab therapy in asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials of patients with moderate and severe persistent asthma showed that anti-IgE therapy significantly reduces severe exacerbations. Many patients can also significantly reduce their need for inhaled glucocorticoids (",
"      <a class=\"graphic graphic_figure graphicRef72697 \" href=\"UTD.htm?18/15/18687\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81434 \" href=\"UTD.htm?26/8/26766\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Xolair is the only available preparation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      and is approved for use as an add-on therapy in patients with inadequately controlled moderate to severe asthma despite the use of ICS therapy at appropriate doses. The 2007 National Asthma Education and Prevention Program (NAEPP) asthma guidelines recommended that omalizumab be considered as adjunctive therapy in step 5 or 6 care for patients with allergies and severe persistent asthma (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7764932\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      is administered by subcutaneous injection under medical supervision. No specific laboratory tests are suggested for monitoring patients who are responding clinically to anti-IgE therapy. Total serum IgE levels are not helpful because these do not distinguish free IgE from IgE complexed to the drug, and total IgE levels typically increase three to sixfold on therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      is generally well tolerated. Anaphylaxis occurs in approximately 1 to 2 in 1000 patients, and can develop after any dose, including the first one, or have a delayed onset or a protracted course. Professional allergy societies in the United States have proposed that patients be observed for two hours after each of the first three injections, and for 30 minutes after each subsequent injection, in addition to other precautions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other novel strategies to reduce the effects of IgE in atopic disease include monoclonal antibodies to CD23, the low affinity IgE receptor, and cytokine modulators designed to decrease IgE production. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Other novel strategies to reduce IgE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/1\">",
"      Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999; 402:B18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/2\">",
"      Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/3\">",
"      Gauchat JF, Lebman DA, Coffman RL, et al. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990; 172:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/4\">",
"      de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999; 103:S492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/5\">",
"      Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999; 402:B24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/6\">",
"      Tsicopoulos A, Joseph M. The role of CD23 in allergic disease. Clin Exp Allergy 2000; 30:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/7\">",
"      Weinmayr G, Weiland SK, Bj&ouml;rkst&eacute;n B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med 2007; 176:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/8\">",
"      Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/9\">",
"      Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007; 120:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/10\">",
"      Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004; 114:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/11\">",
"      Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/12\">",
"      Zieg G, Lack G, Harbeck RJ, et al. In vivo effects of glucocorticoids on IgE production. J Allergy Clin Immunol 1994; 94:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/13\">",
"      Jabara HH, Brodeur SR, Geha RS. Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001; 107:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/14\">",
"      Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/15\">",
"      Fick RB Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999; 5:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/16\">",
"      Haselden BM, Kay AB, Larch&eacute; M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000; 122:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/17\">",
"      Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/18\">",
"      The Pink Sheet. FDC Reports. Chevy Chase, MD. 2003; 65:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/19\">",
"      Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther 2003; 45:67.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/21\">",
"      Campbell JM, Wofford JD, Knutsen AP. Omalizumab treatment in children 6 to 18 years old with severe asthma at a children's medical center. Pediatr Asthma Allergy Immunol 2008; 21:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/22\">",
"      Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/23\">",
"      Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/24\">",
"      Johansson SG, Nopp A, Oman H, et al. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/25\">",
"      Ankerst J, Nopp A, Johansson SG, et al. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010; 152:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/26\">",
"      Olivieri M, Biscardo CA, Turri S, Perbellini L. Omalizumab in persistent severe bakers' asthma. Allergy 2008; 63:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/27\">",
"      Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/28\">",
"      Easthope S, Jarvis B. Omalizumab. Drugs 2001; 61:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/29\">",
"      MacGlashan DW Jr. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 1993; 91:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/30\">",
"      MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/31\">",
"      Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162:5624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/32\">",
"      Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/33\">",
"      Gomez G, Jogie-Brahim S, Shima M, Schwartz LB. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol 2007; 179:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/34\">",
"      MacGlashan DW Jr, Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 2012; 130:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/35\">",
"      Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012; 130:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/36\">",
"      Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/37\">",
"      Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/38\">",
"      Corren J, Shapiro G, Reimann J, et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008; 121:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/39\">",
"      Boulet LP, Chapman KR, C&ocirc;t&eacute; J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/40\">",
"      Djukanovi�� R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/41\">",
"      Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; :CD003559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/42\">",
"      Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/43\">",
"      Sol&egrave;r M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/44\">",
"      Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/45\">",
"      Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/46\">",
"      Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/47\">",
"      Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010; 151:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/48\">",
"      Holgate ST, Chuchalin AG, H&eacute;bert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/49\">",
"      Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/50\">",
"      Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/51\">",
"      Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/52\">",
"      Busse WW, Massanari M, Kianifard F, Geba GP. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Curr Med Res Opin 2007; 23:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/53\">",
"      Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/54\">",
"      Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/55\">",
"      Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012; 97:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/56\">",
"      Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011; 127:398.",
"     </a>",
"    </li>",
"    <li>",
"     Dosing charts are available in the manufacturers prescribing information. Available online at file://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/58\">",
"      Asai N, Ohkuni Y, Komatsu A, et al. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE. J Bras Pneumol 2011; 37:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/59\">",
"      Sugino Y, Sanda R, Takagi Y, et al. [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens]. Arerugi 2010; 59:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/60\">",
"      Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/61\">",
"      Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/62\">",
"      Fahy JV. Reducing IgE levels as a strategy for the treatment of asthma. Clin Exp Allergy 2000; 30 Suppl 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/63\">",
"      Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/64\">",
"      Menzella F, Facciolongo N, Castagnetti C, et al. Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 2009; 41:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/65\">",
"      Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother 2004; 38:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/66\">",
"      Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005; 303:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/67\">",
"      Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med 2012; 106:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/68\">",
"      Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/69\">",
"      Slavin RG, Ferioli C, Tannenbaum SJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/70\">",
"      Nopp A, Johansson SG, Ad&eacute;doyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/71\">",
"      The Pink Sheet. FDC Reports. Chevy Chase, MD. 2003; 65:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/72\">",
"      Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/73\">",
"      Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007; 120:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/74\">",
"      Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011; 43:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/75\">",
"      Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180:637.",
"     </a>",
"    </li>",
"    <li>",
"     Genentech, Inc. Omalizumab (Xolair) Review of clinical safety data. www.fda.gov/ohrms/dockets/ac/03/briefing/3952B1_02_FDA-Xolair-Safety.pdf (Accessed on April 27, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/77\">",
"      Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/78\">",
"      Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009; 103:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/79\">",
"      Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/80\">",
"      Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/81\">",
"      Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma &amp; Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/82\">",
"      Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28:313.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. 2007 Safety alerts for drug, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/safety/2007/safety07.htm#Xolair (Accessed on January 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/84\">",
"      Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/85\">",
"      Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 2010; 105:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/86\">",
"      Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 2011; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/87\">",
"      Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/88\">",
"      Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972.",
"     </a>",
"    </li>",
"    <li>",
"     Omalizumab (marketed as Xolair) - Early communication about an ongoing safety review. Available on the website of the U.S. Department of Health and Human Services. www.accessdata.fda.gov/scripts/cder/drugsatfda/ (Accessed on August 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/90\">",
"      Jardieu PM, Fick RB Jr. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999; 118:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/91\">",
"      Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007; 37:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/92\">",
"      Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/93\">",
"      Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/94\">",
"      Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/95\">",
"      Mankad VS, Burks AW. Omalizumab : other indications and unanswered questions. Clin Rev Allergy Immunol 2005; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/96\">",
"      Kopp MV, Stenglein S, Kamin W, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007; 18:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/97\">",
"      Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/98\">",
"      Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/99\">",
"      Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/100\">",
"      Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/101\">",
"      Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/102\">",
"      Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/103\">",
"      Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119:1279; author reply 1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/104\">",
"      Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/105\">",
"      Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/106\">",
"      P&eacute;rez-de-Llano LA, Vennera MC, Parra A, et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011; 66:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/107\">",
"      Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double���blind, parallel���group, placebo���controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/108\">",
"      Beck LA, Saini S. Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 2006; 55:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/109\">",
"      Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/110\">",
"      Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/111\">",
"      Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis 2007; 80:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/112\">",
"      Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/113\">",
"      Schmitt J, Sch&auml;kel K. [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit]. Hautarzt 2007; 58:128, 130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/114\">",
"      Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/115\">",
"      Rosenwasser LJ, Meng J. Anti-CD23. Clin Rev Allergy Immunol 2005; 29:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/116\">",
"      Rosenwasser LJ, Busse WW, Lizambri RG, et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003; 112:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/117\">",
"      Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/118\">",
"      Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004; 3:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/119\">",
"      Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/120\">",
"      Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/121\">",
"      Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/46/17130/abstract/122\">",
"      Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995; 95:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 545 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17130=[""].join("\n");
var outline_f16_46_17130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ROLE OF IgE IN ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effects of other therapies on IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7765588\">",
"      OMALIZUMAB THERAPY IN ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7764932\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7765369\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7765376\">",
"      - Occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7599108\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7766019\">",
"      - Patients with severe asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7599115\">",
"      - Impact on acute allergen exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pretreatment testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7765170\">",
"      - Route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7765129\">",
"      - Time to effect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Monitoring therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7765080\">",
"      - Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7765756\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7766245\">",
"      - Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recommended precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H28924393\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7766260\">",
"      - Urticaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Injection site reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Serum sickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Safety in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ANTI-IgE THERAPY IN OTHER DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER NOVEL STRATEGIES TO REDUCE IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anti-CD23",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cytokine modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/545\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/545|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/26/33191\" title=\"figure 2\">",
"      Omalizumab mechansim",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/25/14750\" title=\"figure 3\">",
"      Anti-IgE trial design",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/15/18687\" title=\"figure 4\">",
"      Effect of Anti-IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/8/26766\" title=\"figure 5\">",
"      ICS reduction with Anti-IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=related_link\">",
"      Chronic urticaria: Treatment of refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/39000?source=related_link\">",
"      Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14489?source=related_link\">",
"      Occupational asthma: Management, prognosis, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31848?source=related_link\">",
"      The biology of IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=related_link\">",
"      Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_46_17131="Symptoms of DGI";
var content_f16_46_17131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major symptoms and signs of disseminated gonococcal infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom or sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percentage of patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migratory polyarthralgia",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenosynovitis",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Purulent arthritis",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        One joint",
"       </td>",
"       <td class=\"sublist_other\">",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        More than one joint",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary symptoms",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: O'Brien, JP, Goldenberg, DL, Rice, PA, Medicine 1983; 62:395.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17131=[""].join("\n");
var outline_f16_46_17131=null;
var title_f16_46_17132="Pretest probability of CHD in CASS";
var content_f16_46_17132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pretest probability of coronary heart disease (CHD) and accuracy of exercise test in the CASS population",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gender",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of CHD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False negative, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite angina",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definite angina",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable angina",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probable angina",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonischemic chest pain",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonischemic chest pain",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The Coronary Artery Surgery Study (CASS) examined in part the pretest probability of coronary heart disease (CHD) and the accuracy of exercise testing among patients presenting with complaints of chest pain. The exercise test was considered positive when there was &ge;1 mm ST segment depression or elevation for at least 0.08 sec compared to the baseline ECG. When patients were divided into subgroups based upon gender and the quality of their chest pain complaints, the pretest probability of CHD (as determined by coronary angiography) varied between 5 and 89 percent and the false positive and negative rates of exercise testing varied between 4 and 94 and 5 and 65 percent, respectively. The higher false positive rate in women compared to men could be explained by the lower prevalence of CHD in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Weiner DA, Ryan TJ, McCabe CH, et al. N Engl J Med 1979; 301:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17132=[""].join("\n");
var outline_f16_46_17132=null;
var title_f16_46_17133="Differential dx for hypothermia";
var content_f16_46_17133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hypothermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Mechanism",
"         </td>",
"         <td class=\"subtitle1\">",
"          Clinical disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"1\" rowspan=\"14\">",
"          Increased heat loss",
"         </td>",
"         <td>",
"          Environmental exposure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Induced vasodilation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Drugs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Alcohol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Toxins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Skin disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Burns",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Psoriasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Exfoliative dermatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Iatrogenic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cold infusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Emergent deliveries",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cardiopulmonary bypass",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Continuous renal replacement therapy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"1\" rowspan=\"11\">",
"          Decreased heat production",
"         </td>",
"         <td class=\"sublist1_start\">",
"          Endocrinologic disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypopituitarism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypoadrenalism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypothyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Insufficient fuel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypoglycemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Malnutrition",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Neuromuscular inefficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Extremes of age",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Impaired shivering",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Inactivity",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1\">",
"          Mechanism",
"         </td>",
"         <td class=\"subtitle1\">",
"          Clinical disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"1\" rowspan=\"12\">",
"          Impaired regulation",
"         </td>",
"         <td class=\"sublist1_start\">",
"          Peripheral",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Spinal-cord transection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Neuropathies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diabetes mellitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Central",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cerebrovascular accident",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Subarachnoid hemorrhage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Parkinsonism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypothalamic dysfunction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Multiple sclerosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Anorexia nervosa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Drugs: Intoxicants, anxiolytics, antidepressants, antimanic agents, antipsychotics, opioids, oral antihyperglycemics, beta blockers",
"         </td>",
"        </tr>",
"        <tr>",
"         <td colspan=\"1\" rowspan=\"6\">",
"          Other",
"         </td>",
"         <td>",
"          Sepsis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pancreatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carcinomatosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Uremia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vascular insufficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trauma",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Hanania, NA, Zimmerman, JL. Accidental hypothermia. Critical Care Clinincs 1999; 15:235. Copyright &copy;1999 WB Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17133=[""].join("\n");
var outline_f16_46_17133=null;
var title_f16_46_17134="Word catheter";
var content_f16_46_17134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Word catheter (used for Bartholin gland cyst or abscess)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Uninflated; (B) Instilled with water.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17134=[""].join("\n");
var outline_f16_46_17134=null;
var title_f16_46_17135="Frykman I radius fracture AP view";
var content_f16_46_17135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman I radius fracture AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This x-ray, taken of a 23-year-old snowboarder after she fell back onto her outstretched left hand, shows a Frykman I distal radius fracture. The x-ray shows several abnormalities including a significant loss of radial height, decreased radial inclination, and positive ulnar variance. Also, several fracture lines are present (black arrows), indicating comminution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_46_17135=[""].join("\n");
var outline_f16_46_17135=null;
